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1. Summary 
 
Human cytomegalovirus (HCMV) is one of the most common opportunistic infective 
agents in immunocompromised individuals, such as AIDS patients and organ transplant 
recipients, and causes the most frequent congenital infection in humans. Existing antiviral 
treatments are limited by severe drawbacks, i.e. poor bioavailability, toxicity and limited 
effectiveness mainly due to the development of drug resistant viruses. Thus, there is 
continuous need for new and effective anti-cytomegalovirus agents. The viral protease, 
which functions during assembly and maturation of the capsid and which is essential for 
the production of infectious virus, represents a promising drug target. 
In Parts I and II of this PhD thesis I describe the development of two growth 
selection systems that monitor HCMV protease activity in yeast cells. In the LexA-M 
system (Part I) the cleavage site of HCMV protease is inserted between the DNA-binding 
domain of LexA and the activating domain of the transcription factor Gal4p. Cleavage by 
the viral protease inactivates the likewise engineered transcription factor, thereby causing 
a stop in transcription of a downstream cloned LexA-Gal4p regulated HIS3 growth 
selection gene. Such yeast cells do not grow in selective medium lacking histidine. 
However, addition of a protease inhibitor allows expression of the HIS3 gene resulting in 
stimulation of cell growth.  
In the Trp1-M system (Part II), the HCMV protease cleavage site is inserted in 
Trp1p, a yeast protein essential for cell proliferation in medium lacking tryptophan. 
Functional inactivation of this modified Trp1p by the viral protease prevents cell growth, 
whereas addition of validated protease inhibitors results in stimulation of cell 
proliferation. Importantly, both systems rely on a positive read-out and therefore directly 
select for non-toxic compounds.  
In Part III of this thesis, the LexA-M system was applied to a high-throughput 
screening (HTS) for the identification of HCMV protease inhibitors. A library of 15’000 
small molecules was screened in a fully automated manner. We obtained 67 confirmed 
hits, which stimulated growth in yeast in a concentration-dependant manner. These 67 
hits were further investigated in biochemical and mammalian cell-based assays. 8 of them 
showed good antiviral properties in cell culture in the 2-digit µM range; however no 
evidence was obtained for a direct binding to the protease. 
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1. Résumé 
 
Le cytomégalovirus est l’un des agents infectieux les plus communs chez les personnes 
immunodéficitaires, tels que les malades du SIDA ou les receveurs de greffe. Ce virus 
cause aussi fréquemment des infections congénitales. Les traitements existants sont 
limités par des défauts majeurs: mauvaise absorption, toxicité, efficacité restreinte à 
cause du développement de souches virales résistantes aux médicaments. Il y a donc un 
évident besoin de nouvelles thérapies. La protéase du cytomégalovirus, responsable de 
l’assemblage et de la maturation de la capside, est essentielle pour la production de virus 
infectieux, et représente donc une cible prometteuse pour le développement de nouveaux 
médicaments. 
Dans les parties I et II de cette thèse, je décris le développement de deux systèmes 
de sélection qui mesurent l’activité de la protéase du cytomégalovirus dans la levure. 
Dans les deux systèmes, l’activité de la protéase est reflétée par un ralentissement de la 
prolifération cellulaire. Dans le système LexA-M  (Partie I), le site de clivage de la 
protéase est inséré entre le domaine de LexA se liant à l’ADN et le domaine activateur du 
facteur de transcription Gal4p. Le clivage par la protéase inactive ce facteur de 
transcription hybride, causant ainsi un arrêt de la transcription du gène rapporteur HIS3. 
En conséquence, ces cellules ne peuvent pas proliférer dans un milieu sélectif sans 
histidine. Cependant, l’ajout d’inhibiteurs de protéase au milieu de culture permet 
l’expression du gène HIS3 et ainsi stimule la croissance  cellulaire. 
Dans le système Trp1-M  (Partie II), le site de clivage de la protéase est inséré 
dans la chaîne polypeptidique de Trp1p, une protéine de levure essentielle à la synthèse 
du tryptophane. L’inactivation de cette enzyme par la protéase empêche la prolifération 
cellulaire en milieu sans tryptophane, alors que l’ajout d’inhibiteurs de protéase la 
relance. Les deux systèmes reposent ainsi sur un read-out positif et donc sélectionnent 
directement des composés non toxiques. 
Dans la troisième partie de cette thèse, le système LexA-M a été utilisé pour un 
screen à large échelle visant à identifier des inhibiteurs de la protéase du 
cytomégalovirus. Une librairie de 15'000 molécules a été criblée de manière entièrement 
automatisée. Nous avons obtenu 67 hits qui ont stimulé la prolifération de levures de 
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manière dose-dépendante. Ces 67 hits ont ensuite été évalués par des tests biochimiques 
et cellulaires. Parmi eux, 8 ont fait preuve de bonnes propriétés antivirales en culture 
cellulaire, mais l’interaction directe entre ces inhibiteurs putatifs et la protéase n’a pas pu 
être démontrée.  
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2.  Introduction 
 
2.1. The cytomegalovirus 
 
Human cytomegalovirus (HCMV) is a member of the herpesviridae family. To date, 8 
human herpes viruses are known. They are classified in 3 subfamilies: the 
alphaherpesvirinae, characterized by a variable host range, a short replicative cycle and a 
rapid spread in culture; the betaherpesvirinae, characterized by their high level of host 
specificity, their slow replication cycle and the spread of infection from cell to cell in cell 
culture; and the gammaherpesvirinae, characterized by a host range limited to the host 
family and the replication in lymphoblastoïd cells (Fields, Knipe et al. 1996).  Besides the 
cytomegalovirus, the betaherpesvirinae subfamily also includes human herpesvirus 6 
(HHV-6) and HHV-7. Alphaherpesvirinae family comprises herpes simplex virus types 1 
and 2 (HSV1 and HSV2), varicella-zoster virus (VZV), and HHV-8, also known as 
Kaposi’s sarcoma related herpesvirus (KSHV). The last subfamily, the 
gammaherpesvirinae, contains the Epstein-Barr virus (EBV) (Fields, Knipe et al. 1996). 
Diseases caused by these viruses are varied (Table 1), but generally benign in 
immunocompetent hosts: HSV1 and 2 cause respectively labial and genital herpes, VZV 
is responsible for chickenpox and shingles, EBV causes mononucleosis, also called 
kissing disease. In many cases, infections with these viruses are even asymptomatic. In 
contrast, immunocompromised patients generally suffer from much more severe 
affection, like herpes zoster (VZV), pneumonia (CMV), hepatitis (HSV1), and patients 
infected with HHV-6 and 7 often reject grafts (Wathen 2002; Coen and Schaffer 2003). 
Moreover, all herpesviruses severely affect embryonic development when primarily 
infection occurs during pregnancy (Fields, Knipe et al. 1996), causing diseases like 
jaundice, chorioretinitis, or permanent neurological damage (e.g. mental retardation, 
deafness, motor deficits). 
The cytomegalovirus consists of a single molecule of linear double strand DNA 
with approximately 230’000 base pairs enclosed by an icosahedral capsid and an 
envelope (Figure 1). The mature viral particle has a diameter of 150-200 nm. A layer of 
amorphous material called tegument surrounds the nucleocapsid. The envelope harbors 
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glycoprotein complexes that are recognized by cell surface receptors (Seitz, Burger et al. 
2001).  
At the beginning of the virus replication cycle (Figure 2), viral glycoproteins bind 
to cell surface receptors, which initiates fusion of the two membranes. The capsid is 
internalized and transported to the nucleus. In the nucleoplasm, the genome is released 
and circularized. First, the early genes coding mainly for transcription factor and enzymes 
needed for the DNA replication are transcribed, followed by the late genes coding for 
capsid and teguments proteins. An empty intermediate capsid is assembled, and viral 
DNA is packed in it. Teguments bind to the nuclear membrane, and viral envelope is 
acquired by budding through it. Virions are released by transport via the endoplasmic 
reticulum to the cell surface (Coen and Schaffer 2003). 
During the lytical phase, the virus is transmitted via cell to cell contacts to 
different organs, in particular salivary glands, kidney, bone marrow and peripheral blood 
monocytes, where it stays silent during the latency phase (Seitz, Burger et al. 2001). 
During that phase, the genome remains with 10 to 100 episomal copies in the nucleus of 
host cells, but no viral protein is produced (Fields, Knipe et al. 1996). This long-term 
latent infection, with periods of recurring viral replication, is a feature common to 
herpesviruses. Reactivation of the lytical phase is induced by different forms of stress or 
immune suppression.  
HCMV can be transmitted via saliva, sexual contact, placental transfer, 
breastfeeding, blood transfusion or transplantation (Gandhi and Khanna 2004). 
Estimation for the seroprevalence of HCMV amounts to 50-70% in healthy adults, and up 
to 90% of the urban population is infected (Martinez, Castro et al. 2001). In Third World 
countries, the prevalence can even reach 100% (Seitz, Burger et al. 2001). But except for 
some cases of mononucleosis-like illness, infection with HCMV rarely causes disease in 
immunocompetent individuals. However, the clinical importance of this virus has 
increased substantially over the past 30 years due to the advent of organ transplantation 
and the emergence of the AIDS epidemic. Indeed, immunocompromised patients develop 
severe illness after the reactivation or the infection with HCMV, and they usually require 
antiviral treatments for a lifetime (Martinez, Castro et al. 2001).  
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2.2. Current antiviral treatments 
 
Antiviral agents currently licensed for the treatment of HCMV infections are ganciclovir, 
valganciclovir, foscarnet, cidofovir and fomivirsen (De Clercq 2003) (See Table 1). With 
the exception of fomivirsen, which blocks the expression of immediate early mRNA, all 
these drugs are nucleoside analogues that target the viral DNA polymerase. Unfortunately 
for the patients affected, the clinical usefulness of these drugs is limited because they 
cause toxic side effects and they need to be injected either intravenously or intraocularly. 
Only valganciclovir is orally available, but there is no evidence that this drug is 
equivalent to the “gold standard” ganciclovir in terms of efficacy and safety (Preiksaitis 
2005). Moreover, even if these drugs reduce viral proliferation in patients, they cannot 
clear the virus completely, and this predisposes to the development of viral drug 
resistances. HCMV strains with reduced susceptibility to ganciclovir, cidofovir and 
fomivirsen during long-term therapy have already been documented (Mulamba, Hu et al. 
1998; Abraham, Lastere et al. 1999). 
Thus, improved alternatives are needed for treating HCMV infections. While in 
the last decades efforts were invested mostly in nucleoside analogues that inhibit DNA 
polymerase, a new interest appears for drugs that target other processes necessary for the 
virus life-cycle: virus-induced cell fusion, viral transcription, viral protein synthesis and 
processing, capsid maturation, viral DNA cleavage and packaging. A number of research 
programs have identified novel classes of small molecules that inhibit these processes, 
but most of them are still in the preclinical or early clinical phases of drug development 
(De Clercq 2003). 
 
2.3. The cytomegalovirus protease as a target 
 
Herpesviruses encode a serine protease, which cleaves the assembly protein precursor 
(pAP), a major component of the intermediate capsid (Kan 1998). Studies on HSV-1 
protease, homologous to HCMV protease, showed that this cleavage is essential for the 
infectivity of the virus (Preston, Coates et al. 1983; Gao, Matusick-Kumar et al. 1994). 
HCMV protease is expressed as a 708-amino-acid precursor, product of the open reading 
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frame UL80a, and cleaves autocatalytically at three consensus sequences called 
maturational (M), release (R) and internal (I) sites (Figure 3) (Waxman and Darke 2000). 
M-site cleavage of the precursor eliminates a 6-kDa carboxyl tail, which mediates 
interaction with the major capsid protein (MCP) at the earliest stage of capsid assembly. 
R-site cleavage separates the N-terminal 29 kDa proteolytic domain from the C-terminal 
38 kDa scaffolding domain. In contrast to M- and R-site that are required to produce 
infectious virus (Gibson 1996), the I-site cleavage, which produces a two chains protease, 
is not essential, even though Loveland et al. recently showed that this cleavage enhances 
infectivity (Loveland, Chan et al. 2005). The assembly precursor (pAP) is transcribed and 
translated from a UL80.5 ORF nested in the UL80a, and therefore contains the same 38 
kDa domain like the C-terminal scaffolding domain of pPR. 
Wade Gibson (Gibson 2001) proposed a model for the function of HCMV 
protease in the capsid assembly (Figure 4): in the cytoplasm, the protease precursor 
(pPR), the assembly protein precursor (pAP) and the major capsid protein (MCP) form 
oligomers that translocate into the nucleus and assemble in spherical procapsid. There, 
the close proximity and the concentration increase of the protease precursor proteins 
promote their dimerization and subsequent activation. Once activated, the protease 
precursors cleave their own M-site and that of the assembly precursors, and cleavage 
products are then eliminated from the capsid cavity, making room for DNA packaging.  
Whether the 29 kDa mature protease or the 75kDa protease precursor is the 
physiologically relevant form responsible for capsid maturation is still a matter of debate. 
For Robertson et al. (Robertson, McCann et al. 1996), cleavage at M- and R-sites occurs 
after the assembly of the procapsid in the nucleus and involves most likely the precursor 
form. For Waxman and Dark (Waxman and Darke 2000), the precursor form of the 
enzyme would rather be the initiating catalyst for subsequent processing performed by 
the mature protease. Most of enzymology and inhibition studies to date have been 
performed with the 29 kDa mature form of the protease (Pinko, Margosiak et al. 1995; 
Bonneau, Grand-Maitre et al. 1997; Khayat, Batra et al. 2003), though the precursor form 
of HCMV protease has been demonstrated to be catalytically active as well (Welch, 
McNally et al. 1993; Wittwer, Funckes-Shippy et al. 2002).  
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HCMV protease shares considerable amino acid identity with the other 
herpesvirus proteases: about 40% with HHV-6 (betaherpesvirinae), and still 26% with 
VZV, HSV-1 and HSV-2, (alphaherpesvirinae) (Qiu, Janson et al. 1997). However, 
herpesvirus proteases do not share any homology with classical serine proteases. X-ray 
crystallography studies show that they have unique backbone folds, containing a central, 
mostly antiparallel seven-stranded β-barrel surrounded by eight helices, and that this 
structural feature is well conserved among the proteases of the three herpesvirus 
subfamilies (Tong 2002). The active site of herpesvirus proteases is located on the 
surface of the β-barrel and contains a novel Ser-His-His catalytic triad. The presence of 
the second His residue is unprecedented, as most classical serine proteases contain an 
acidic residue (Asp or Glu) as the third member. This His third member makes a much 
smaller contribution to the catalysis by herpesvirus proteases (Khayat, Batra et al. 2001), 
which as a consequence are slow enzymes: HSV-1 and HCMV protease have catalytic 
efficiencies (kcat/Km) of 38 s-1 M-1, and 404 s-1 M-1 respectively, as compared for example 
with chemotrypsin, which catalytic efficiency is about 107 s-1 M-1 (Hall and Darke 1995). 
Biochemical studies showed that herpesvirus proteases exist in solution in a 
monomer-dimer equilibrium, and that only the dimer is catalytically active. The HCMV 
protease dimer has a Kd of 8 µM in the absence of glycerol, and of 1.9 nM, in presence of 
25% glycerol (Margosiak, Vanderpool et al. 1996). Indeed, it has been shown that 
kosmotropic agents, such as glycerol but also phosphates, sulfates or acetates, enhance 
protease catalytic activity by stabilizing the dimer configuration (Yamanaka, DiIanni et 
al. 1995; Waxman and Darke 2000). As illustrated in Figure 5, each monomer of HCMV 
protease has an active site, and these active sites do not interact with each other, as 
opposed to many other dimeric proteases where the two monomers form one active site.  
The HIV aspartic protease for example is a homodimer harboring its active site at the 
dimer interface, with each monomer contributing one of the catalytic Asp residues (Tong 
2002). 
Many efforts have been invested to identify cytomegalovirus protease inhibitors. 
Pharmaceutical companies, but also academic laboratories, worked at the development of 
different classes of compounds, for example benzoxazinones (Flynn, Abood et al. 1997), 
monobactams (Ogilvie, Yoakim et al. 1999), or naphthalene derivates (Gopalsamy 2004). 
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In most cases, inhibitors target the active site by acylating the catalytic serine 132, or 
alternatively they oxidize the conserved cysteine 161, which is in close proximity to the 
active site. Recently, Borthwick et al. reported a series of translactams with IC50 values in 
the nanomolar range in both in vitro and cell culture assays. These drug candidates 
showed no cytotoxicity and good pharmakokinetics (Borthwick, Davies et al. 2003; 
Borthwick 2005). However, no clinical trial was reported so far. 
 
2.4.  Biochemical versus cellular assays 
 
Traditionally, protease activity has been measured in vitro with assays using the isolated 
protease and a purified peptide or protein substrate. All published drug discovery 
programs that have targeted the HCMV protease to this day have been based on in vitro 
assays. To monitor HCMV protease activity, a series of peptides have been prepared that 
derive from the M- or the R-cleavage site. Their lengths vary from 4 to 16 amino acids, 
and they are often coupled to chemical structures that allow cleavage detection by 
different methods: fluorescence, radioactivity or colorimetry. The amino acid sequences 
of these peptides substrates have been optimized to improve the kcat/kM of the reaction, 
leading to substrates certainly very efficiently cleaved, but also sometimes far away from 
the natural M- or R- cleavage sequences (Bonneau, Plouffe et al. 1998).  Moreover, 
HCMV protease in vitro assay buffers contain either glycerol or kosmotropic salts (or 
both) in high concentrations to promote dimerization of the enzyme. Thus, in vitro assay 
conditions do not really reflect the physiological environment of the protease. This might 
be an explanation why most inhibitors developed so far are very potent in enzymatic 
assays, but poorly active in cell culture.  
For the following reasons, more effort should be invested in cell-based assays to 
screen for HCMV protease inhibitor: 1. In the cell, protease conformation and activity are 
examined in a cytoplasmic context that is closer to natural physiological state than the 
buffers of in vitro assays. 2. This physiological environment also allows a selection for 
non-toxic compounds, which are metabolically stable and able to permeate membranes. 
3. No purification of the enzyme is required, avoiding a time consuming and costly 
process to obtain an active target.  
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Ideally, compounds should be tested in human cells, since they provide the most 
physiologically relevant system. However, human cells are expensive to culture and 
difficult to propagate in automated HTS systems. Yeasts, which are prototypes of 
eukaryotic cells, are in comparison very convenient tools, fast growing, cheap, easy to 
modify genetically, and can be handled in semi-sterile conditions (Barberis 2002).  
A critical limitation associated with yeast-based screening of small molecules is 
imposed by the lower drug sensitivity of wild-type yeast compared with higher 
eukaryotic cells (Rogers, Decottignies et al. 2001). This difference in drug sensitivity has 
been mostly attributed to very efficient compound efflux by ABC transporters that lower 
the intracellular concentration of compounds. However, intracellular drug accumulation 
in yeast can be enhanced by deleting the major ABC transporters, Pdr5p, Snq2p and Yor1 
(Kolaczkowski, Kolaczowska et al. 1998).  
 
2.5. Conclusion 
 
In this study, I describe in a first part two cellular growth selection systems for the 
identification of inhibitors of HCMV protease. In these systems, yeast cells expressing 
the HCMV protease present a slow growth phenotype, and a normal proliferation rate is 
restored upon inactivation of the protease activity. In a second part, I will relate how 
these yeast growth selection systems were used for screening a 15’000 compound library, 
and how the hits originally identified from that screen were tested in different 
biochemical and antiviral assays.  
 11
2.6 References 
 
Abraham, B., S. Lastere, et al. (1999). “Ganciclovir resistance and UL97 gene mutations 
in cytomegalovirus blood isolates from patients with AIDS treated with 
ganciclovir.” J Clin Virol 13(3): 141-8. 
Barberis, A. (2002). “Cell-based high-throughput screens for drug discovery.” European 
BioPharmaceutical Review(winter). 
Bonneau, P. R., C. Grand-Maitre, et al. (1997). “Evidence of a conformational change in 
the human cytomegalovirus protease upon binding of peptidyl-activated carbonyl 
inhibitors.” Biochemistry 36(41): 12644-52. 
Bonneau, P. R., C. Plouffe, et al. (1998). “Design of fluorogenic peptide substrates for 
human cytomegalovirus protease based on structure-activity relationship studies.” 
Anal Biochem 255(1): 59-65. 
Borthwick, A. D. (2005). “Design of translactam HCMV protease inhibitors as potent 
antivirals.” Med Res Rev 23: 23. 
Borthwick, A. D., D. E. Davies, et al. (2003). “Design and synthesis of pyrrolidine-5,5'-
trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-
based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and 
plasma stability.” J Med Chem 46(21): 4428-49. 
Coen, D. M. and P. A. Schaffer (2003). “Antiherpesvirus drugs: a promising spectrum of 
new drugs and drug targets.” Nat Rev Drug Discov 2(4): 278-88. 
De Clercq, E. (2003). “New inhibitors of human cytomegalovirus (HCMV) on the 
horizon.” J Antimicrob Chemother 51(5): 1079-83. Epub 2003 Apr 14. 
Fields, B. N., D. M. Knipe, et al. (1996). Fields Virology. Philadelphia: Lippincott-
Raven. 
Flynn, D. L., N. A. Abood, et al. (1997). “Recent advances in antiviral research: 
identification of inhibitors of the herpesvirus proteases.” Curr Opin Chem Biol 
1(2): 190-6. 
Gandhi, M. K. and R. Khanna (2004). “Human cytomegalovirus: clinical aspects, 
immune regulation, and emerging treatments.” Lancet Infect Dis 4(12): 725-38. 
 12
Gao, M., L. Matusick-Kumar, et al. (1994). “The protease of herpes simplex virus type 1 
is essential for functional capsid formation and viral growth.” J Virol 68(6): 3702-
12. 
Gibson, W. (1996). “Structure and assembly of the virion.” Intervirology 39(5-6): 389-
400. 
Gibson, W. (2001). “Action at the assemblin dimer interface. [letter; comment.].” Nat 
Struct Biol 8(9): 739-741. 
Gopalsamy, A. L., K.; O'Connell J.O (2004). “Design and Syntheses of 1,6-Naphtalene 
Derivatives as Selective HCMV Protease Inhibitors.” Journal of Medicinal 
Chemistry. 
Hall, D. L. and P. L. Darke (1995). “Activation of the herpes simplex virus type 1 
protease.” Journal of Biological Chemistry 270(39): 22697-700. 
Kan, C.-C. (1998). Cytomegalovirus assemblin (162). Handbook of Proteolytic Enzymes. 
N. D. R. A.J. Barret, J.F. Waessner, academic press: 468-470. 
Khayat, R., R. Batra, et al. (2001). “Investigating the role of histidine 157 in the catalytic 
activity of human cytomegalovirus protease.” Biochemistry 40(21): 6344-51. 
Khayat, R., R. Batra, et al. (2003). “Structural and biochemical studies of inhibitor 
binding to human cytomegalovirus protease.” Biochemistry 42(4): 885-91. 
Kolaczkowski, M., A. Kolaczowska, et al. (1998). “In vivo characterization of the drug 
resistance profile of the major ABC transporters and other components of the 
yeast pleiotropic drug resistance network.” Microb Drug Resist 4(3): 143-58. 
Loveland, A. N., C. K. Chan, et al. (2005). “Cleavage of human cytomegalovirus 
protease pUL80a at internal and cryptic sites is not essential but enhances 
infectivity.” J Virol 79(20): 12961-8. 
Margosiak, S. A., D. L. Vanderpool, et al. (1996). “Dimerization of the human 
cytomegalovirus protease: kinetic and biochemical characterization of the 
catalytic homodimer.” Biochemistry 35(16): 5300-7. 
Martinez, A., A. Castro, et al. (2001). “Recent strategies in the development of new 
human cytomegalovirus inhibitors.” Med Res Rev 21(3): 227-44. 
 13
Mulamba, G. B., A. Hu, et al. (1998). “Human cytomegalovirus mutant with sequence-
dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 
2922).” Antimicrob Agents Chemother 42(4): 971-3. 
Ogilvie, W. W., C. Yoakim, et al. (1999). “Synthesis and antiviral activity of 
monobactams inhibiting the human cytomegalovirus protease.” Bioorg Med 
Chem 7(8): 1521-31. 
Pinko, C., S. A. Margosiak, et al. (1995). “Single-chain recombinant human 
cytomegalovirus protease. Activity against its natural protein substrate and 
fluorogenic peptide substrates.” Journal of Biological Chemistry 270(40): 23634-
40. 
Preiksaitis, J. K. (2005). “Valganciclovir treatment of cytomegalovirus disease: a 
promising but not yet fully validated therapeutic approach.” Am J Transplant 
5(7): 1783. 
Preston, V. G., J. A. Coates, et al. (1983). “Identification and characterization of a herpes 
simplex virus gene product required for encapsidation of virus DNA.” J Virol 
45(3): 1056-64. 
Qiu, X., C. A. Janson, et al. (1997). “Crystal structure of varicella-zoster virus protease.” 
Proceedings of the National Academy of Sciences of the United States of America 
94(7): 2874-9. 
Robertson, B. J., P. J. McCann, 3rd, et al. (1996). “Separate functional domains of the 
herpes simplex virus type 1 protease: evidence for cleavage inside capsids.” 
Journal of Virology 70(7): 4317-28. 
Rogers, B., A. Decottignies, et al. (2001). “The pleitropic drug ABC transporters from 
Saccharomyces cerevisiae.” J Mol Microbiol Biotechnol 3(2): 207-14. 
Seitz, R., R. Burger, et al. (2001). “Human Cytomegalovirus.” Infus Ther Transfus 
med(28): 165-171. 
Tong, L. (2002). “Viral proteases.” Chem Rev 102(12): 4609-26. 
Wathen, M. W. (2002). “Non-nucleoside inhibitors of herpesviruses.” Rev Med Virol 
12(3): 167-78. 
Waxman, L. and P. L. Darke (2000). “The herpesvirus proteases as targets for antiviral 
chemotherapy.” Antiviral Chemistry & Chemotherapy 11(1): 1-22. 
 14
Welch, A. R., L. M. McNally, et al. (1993). “Herpesvirus proteinase: site-directed 
mutagenesis used to study maturational, release, and inactivation cleavage sites of 
precursor and to identify a possible catalytic site serine and histidine.” J Virol 
67(12): 7360-72. 
Wittwer, A. J., C. L. Funckes-Shippy, et al. (2002). “Recombinant full-length human 
cytomegalovirus protease has lower activity than recombinant processed protease 
domain in purified enzyme and cell-based assays.” Antiviral Research 55(2): 291-
306. 
Yamanaka, G., C. L. DiIanni, et al. (1995). “Stimulation of the herpes simplex virus type 
I protease by antichaeotrophic salts.” Journal of Biological Chemistry 270(50): 
30168-72. 
 
 
 15
2.7. Figures  
 
 
From Wathen, M. W. (2002). “Non-nucleoside inhibitors of herpesviruses.” Rev Med Virol 12(3): 167-78. 
 
 
 
 
 
 
Figure 1: Schematic drawing of human cytomegalovirus 
From Gandhi, M. K. and R. Khanna (2004). “Human cytomegalovirus: clinical aspects, immune regulation, 
and emerging treatments.” Lancet Infect Dis 4(12): 725-38. 
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Figure 2. Herpesvirus replication cycle.  
a. Attachment and entry. Viral membrane proteins on virus particles bind to cellular receptors on the 
plasma membrane of the cell, which initiates fusion of the two membranes. Nucleocapsids containing the 
viral genome (red hexagons) are liberated into the cytoplasm and transported to nuclear pores. Viral DNA 
is released into the nucleus and circularizes. b. Transcription. Three classes of viral genes are transcribed 
and translated into proteins. Immediate-early proteins (yellow) participate in further transcription. c. 
Replication. Early proteins (green) synthesize new viral DNA molecules using circularized input DNA as a 
template. d. Assembly, encapsidation and nuclear egress. Late proteins (blue) assemble into capsids, which 
incorporate newly replicated viral DNA. Nucleocapsids leave the nucleus by budding through the inner 
nuclear membrane (a process termed ‘envelopment’) into the perinuclear space. Through a complex 
process of de- and re-envelopment, mature virus particles reach exocytic vesicles, which fuse with the 
plasma membrane and release new virus particles into the extracellular space. 
 
From Coen, D. M. and P. A. Schaffer (2003). “Antiherpesvirus drugs: a promising spectrum of new drugs 
and drug targets.” Nat Rev Drug Discov 2(4): 278-88. 
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Figure 3. CMV assemblin is derived from a precursor. 
The proteinase precursor is encoded by open reading frame UL80a and is autoproteolytically cleaved at the 
maturational (M), release (R), and internal (I) sites. M site cleavage removes the carboxyl 'Tail' and R site 
cleavage releases the proteolytic domain, assemblin. I-site cleavage converts assemblin monomers to 
dimers composed of its amino (An) and carboxyl (Ac) halves. UL80.5 encodes the protease substrate, the 
assembly protein precursor, and is nested, in frame, and 3'-coterminal with UL80a. The amino acid 
sequence of the assembly protein precursor is identical to that of the proteinase scaffolding domain. 
 
From Gibson, W. (2001). “Action at the assemblin dimer interface.” Nat Struct Biol 8(9): 739-741. 
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Figure 4. CMV protease role during capsid maturation.  
Depicted here are cytoplasmic interactions between the proteinase precursor (pPR, red), assembly protein 
precursor (pAP, green), and major capsid protein (MCP, blue) to form oligomers that are competent for 
nuclear translocation and procapsid assembly. The procapsid scaffolding structure (beaded, green/red) 
underlying the shell (blue ring) undergoes rearrangement following proteolytic cleavage and capsid 
angularization. Only a portion of the proteinase precursor remains in the mature, DNA-containing capsid. 
Inset shows functional sequences shared by pPR and pAP: amino conserved domain (ACD), nuclear 
localization signals (NLS) 1 and 2, carboxyl conserved domain (CCD), and maturational (M) site. 
 
From Gibson, W. (2001). “Action at the assemblin dimer interface.” Nat Struct Biol 8(9): 739-741. 
 
 
 
 
Figure 5. Schematic drawing of the dimer of HCMV protease.  
The Ser-His-His catalytic triads are highlighted in blue circles, and the dimer interface in the green oval.  
 
From Batra, R., R. Khayat et al. (2001). “Molecular mechanism for dimerization to regulate the catalytic 
activity of human cytomegalovirus protease.” Nat Struct Biol 8(9)(Sept.): 810-7. 
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3.1.  Part I 
 
A yeast growth selection system based on reporter gene activation 
to detect human cytomegalovirus protease activity 
 
LexA-M system 
 
 
Abstract 
 
The proteolytic processing of the human cytomegalovirus (HCMV) assembly protein is 
an essential step in virion maturation. Here we describe a genetic system in the yeast 
Saccharomyces cerevisiae that monitors the activity of the protease responsible for this 
cleavage. We take advantage of the properties of the yeast transcriptional activator Gal4p, 
which contains two separable and functionally essential domains: the amino-terminal 
binding domain and the carboxy-terminal transcriptional activating domain. In our 
system, the cleavage M-site is inserted between these two domains of Gal4p. Thus, 
proteolysis by HCMV protease inactivates the transcription factor that controls the 
expression of the HIS3 reporter gene, and thereby suppresses yeast survival in minimal 
medium lacking histidine. Cell proliferation in selective medium is only possible when 
the protease is inhibited. This Part I presents key steps in the development of a system for 
the identification of HCMV protease inhibitors.  
 20
1.  Material and Methods 
 
1.1. Yeast strains  
The YDE172 strain, which carries the divergently oriented LacZ and HIS3 genes under 
the control of the natural UASG from the GAL1-GAL10 regulatory sequences integrated 
in the his3∆200 locus, was already described elsewhere (Auf der Maur, Escher et al. 
2001). 
The VCY3 strain is derived from the RLY07 strain (MATa ura3-52 his3∆200 
leu2∆1 trp1∆63 lys2∆385 ∆pdr5 ∆snq2 ∆yor1). To obtain VCY3 the integrating plasmid 
pAdMO2R, which carries the divergently oriented LacZ and HIS3 genes under the 
control of a bi-directional promoter with 6 LexA-binding sites, was linearized at the AflII 
site in the HIS3 3’ untranslated region and integrated into the his3∆200 locus of RLY07. 
To allow the selection of transformants on –His plates, the plasmid pMix02, encoding a 
LexA-Gal4AD transactivator construct and a Ura3p marker, was previously transformed 
in RLY07, and subsequently eliminated by selection on plates containing 0.1% 5-fluoro-
orotic acid (5-FOA). Correct integration of the cassette and loss of pMix02 plasmid were 
confirmed by genomic PCR and functional assays. 
Yeast transformation was performed according to the standard lithium acetate 
protocol (Gietz, St Jean et al. 1992).  
 
1.2. Construction of plasmids 
The pAdMO2R plasmid was obtained by replacing the natural HIS3 promoter in the 
pDE200 integrating plasmid (Escher, Bodmer-Glavas et al. 2000) with the tight LEU2 
promoter, via Sal1 and Spe1 restriction enzymes. The pMix02 plasmid was obtained by 
subcloning the LexA (1-202) -Gal4AD (768-881) transactivator in a 2 micron (2µ) 
plamid, under the control of an ACT4 promoter. 
The HCMV protease cleavage sequence GGVVNA↓SCRLAGG, derived from 
the M-site of the 75 kDa protease precursor, was flanked with unique Nco1 and Not1 
sites, and inserted between the Gal4 (1-147) binding domain and the Gal4 (768-881) 
activating domain by PCR, resulting in the Gal4BD-M-Gal4AD construct. This construct 
was cloned via XbaI and SalI in the pMH28 CEN4-ARS1 plasmid, which contains a 
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truncated ADH1 promoter, a GAL11 terminator and a TRP1 marker. For the experiments 
in the VCY3 strain, the sequence coding for Gal4BD (1-147) has been replaced via XbaI 
and NcoI restriction enzymes by the LexA (1-202) coding region, resulting in the LexA-
M-Gal4AD construct. In order to generate the LexA-Me-Gal4AD construct (Me for M 
extended), the 13 amino acid cleavage sequence was replaced via Nco1 and Not1 sites by 
an extended M-type sequence consisting of 39 amino acids. The LexA-Me*-Gal4AD 
construct bears the mutation A→E at the position P1 of the cleavage site. The UL80a 
gene, coding for the 708 amino acids protease precursor, was obtained by PCR from 
HCMV infected MRC5 human cells and subcloned via unique Xba1 and Not1 sites in 
CEN4-ARS1 or 2µ plasmids carrying a URA3 marker and an ACT4 promoter. The 
HCMV protease gene encoding amino acids 1-256 of the 708 amino acids protease 
precursor was obtained by PCR, using the UL80a gene as template, and subcloned via 
unique Xba1 and Not1 sites in the same plasmids.  
 
1.3. Yeast media and transformation 
Yeast genetic techniques and media were as described (Burke, Dawson et al. 2000). 
Transformation of yeast cells was performed following the lithium acetate method (Gietz, 
St Jean et al. 1992). 
 
1.4. β-galactosidase assay 
The β-galactosidase assay in solution was performed using permeabilized cells as 
described (Burke, Dawson et al. 2000). Activity was normalized to the number of cells 
assayed, which was measured by light scattering (OD600). Each experiment was 
performed twice.  
 
1.5. Liquid growth assay 
YDE172 or VCY3 cells transformed with the plasmids indicated for each experiment in 
the result part were inoculated in 3 mL of 2% glucose -ura -trp drop-out medium and 
grown at 30°C to OD600 1. They were then washed with 5 mL H2O, resuspended in the 
2% glucose –ura –trp –his assay medium supplemented with 10 mM or 30 mM 3-AT 
and/or 10% glycerol, and diluted to a defined start OD600 (exact medium composition and 
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start OD600 are described for each experiment in the result part). At time zero, assay 
cultures were distributed in 96-well microtiter plates (Greiner, # 655101), with a volume 
of 150 µL per well, and incubated without shaking at 30°C. At the time points indicated 
in the results section, plates were shaken 30 s at 1300 rpm to resuspend cells and 
submitted to light scattering measurement at 595 nm in a Tecan Genios reader for 
determining cell density. All assays were conducted with triplicate or quadruplet samples 
and were repeated at least once. 
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2.   Results 
 
2.1.  The principle of the HCMV protease Gal4-M growth selection system 
The system that we describe here derives from a reporter system previously published 
that monitors HCMV protease activity (Lawler and Snyder 1999). To establish this 
system, authors exploited in mammalian cells the two-domain structural property of the 
yeast Gal4p transcription factor in such a way that the cleavage M-site was inserted 
between the two domains of the yeast Gal4p transcription factor. Proteolysis of the hybrid 
substrate interrupted the production of the luciferase reporter protein.  
In our yeast Gal4-M system like in Lawler and Snyder’s system, M-site is inserted 
between the two domains of Gal4p (Figure 1A). Protease activity separates the DNA-
binding domain from the activating domain, causing a transcriptional stop of the yeast 
HIS3 growth marker (Figure 1B). Thus, cells expressing the Gal4BD-M-Gal4AD 
construct alone are expected to proliferate normally in medium lacking histidine, whereas 
cells co-expressing the HCMV protease should stop growing due to the inactivation of 
the Gal4 transcription factor by the protease, which results in the lack of expression of the 
HIS3 reporter gene.  
 
2.2. HCMV protease domain (assemblin), but not the 75 kDa protease precursor,  
is  active in the YDE172 strain 
In order to reproduce in yeast the system established by Lawler and Snyder in 
mammalian cells (Lawler and Snyder 1999), we expressed the 75 kDa protease precursor 
(pPR, encoded by the UL80a gene) and the 13 amino acid cleavage sequence fused 
between the two Gal4p domains in the YDE172 strain. The YDE172 strain contains a bi-
directional promoter that drives the expression of two reporter genes: HIS3 and LacZ. To 
evaluate the potential of i) the Gal4BD-M-Gal4AD construct to activate the reporter gene 
and ii) the 75 kDa pPR to cleave the substrate sequence, we measured reporter gene 
expression by performing a β-galactosidase assay. Figure 2A shows that the Gal4-M 
substrate clearly activated the LacZ reporter. However, no reduction of signal was 
observed upon co-expression of the pPR, meaning either that this enzyme was not 
functional, or that it could not cleave its substrate for sterical reasons. In another 
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approach to detect a cleavage of the Gal4-M substrate, we expressed in YDE172 the 
assemblin instead of the pPR. This 29 kDa mature form of the protease was able to cleave 
the Gal4-M substrate and, furthermore, the cleavage rate was proportional to the 
concentration of protease present in the cell. Indeed, as shown on the Figure 2A, the β-
galactosidase activity induced by the Gal4-M construct was diminished by 46% upon 
addition of the protease expressed from an ACT4 CEN4-ARS1 (see appendix) plasmid, 
and by 72% when the protease was expressed from an ACT4 2µ (see appendix) plasmid.  
However, β-galactosidase assays are not feasible in a fully automated format, 
whereas growth assays are. Therefore, the transformed cells described above for the β-
galactosidase assay were diluted to a start OD600 0.03 and incubated in medium lacking 
histidine during 24 hours. Cells expressing the protease precursor were not tested 
considering that this form of the protease displayed no activity in the β-galactosidase 
assay. As opposed to the results shown in Figure 2A, the assemblin in the growth assay 
showed only little activity. When the protease was expressed from an ACT4 CEN4-ARS1 
plasmid, no growth reduction was observed, and only 30% growth reduction could be 
measured when the protease was expressed from an ACT4 2µ plasmid (Figure 2B). 
 
2.3. A new VCY3 strain with a tight HIS promoter allows a better detection of 
HCMV protease activity in growth assay  
In order to improve the detection of HCMV protease activity, a new yeast strain, VCY3, 
was engineered. In this new strain, the natural HIS3 promoter, which exhibits basal 
expression, was replaced by the tight LEU2 promoter, what greatly improved the signal-
to-noise ratio. Moreover, 6 LexA binding sites replaced the Gal4 UAS of the YDE172. 
Consequently, we replaced the Gal4 binding domain by the LexA protein in the substrate 
construct, thus generating the new LexA-M-Gal4AD construct. 
In the VCY3 strain, the detection in liquid growth assay of LexA-M-Gal4AD 
substrate cleavage by HCMV protease was improved. Upon co-expression of the 
substrate with the protease expressed from an ACT4 CEN4-ARS1 plasmid (Figure 3), a 
reduction of about 20% of cell proliferation was observable after 24 hours incubation in 
selective medium, whereas at the same expression level no protease activity was detected 
in YDE172. And when the protease was expressed from a 2µ plasmid, growth reduction 
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reached 62%, in opposition to 30% in the YDE172 strain. Thus, the new VCY3 strain 
provides a more sensitive read-out for the HIS3 reporter gene than YDE172. In the last 
column of Figure 3, a control experiment is depicted where an enzymatically inactive 
version of HCMV protease carrying the S132A mutation at the active site serine (Chen, 
Tsuge et al. 1996) is investigated. As expected, no growth reduction was observed, 
meaning that this mutant was not able to cleave the LexA-M-Gal4AD substrate. This 
experiment indicates that the growth inhibition observed in presence of active protease 
was indeed due to the catalytic activity of the protease, and not to any toxic effect of the 
protein. 
 
2.4 .     Addition of glycerol increases protease activity 
In the previous experiment, cell proliferation was significantly reduced upon expression 
of the protease from a 2µ plasmid. However, 2µ plasmids are not suitable for high-
throughput screening, since they are present in variable quantities inside the cells after the 
transformation, and thus produce diverse protease amounts in each cell. In contrast, 
CEN4-ARS1 plasmids are present in single exemplar in each transformed cell and 
guaranty constant levels of protease expression. 
In order to promote protease activity and thus get a sufficient reduction of cell 
proliferation upon protease expression from a CEN4-ARS1 plasmid, glycerol was added 
to yeast cultures. This substance had been shown to improve protease activity in vitro by 
promoting dimerization of the protease (Margosiak, Vanderpool et al. 1996). While in the 
absence of glycerol the protease expression from an ACT4 CEN4-ARS1 plasmid resulted 
in a growth reduction of about 20%, with 10% glycerol added to the medium cell 
proliferation was reduced by 54% (Figure 4). Upon expression of the protease from a 2µ 
plasmid, growth reduction in the presence of 10% glycerol was about 95%, compared to 
62% reduction in the absence of glycerol. Cells transformed with the LexA-M-Gal4AD 
transactivator alone and grown in selective medium containing 10% glycerol exhibited 
20% growth reduction in comparison to the same cells grown medium containing no 
glycerol. This mild toxic effect of glycerol is not detrimental to the assay.  
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2.5.      A longer cleavage site facilitates cleavage by the HCMV protease 
In a further attempt to improve HCMV protease cleavage efficiency, we replaced the 13 
amino acid cleavage site by a longer 39 amino acid sequence derived from the M-site of 
the protease precursor protein. This exchange had a double effect: on one side, growth 
induced by the LexA-Me-Gal4AD (Me stands for M elongated) transactivator was 
increased about 3 folds, and on the other side cleavage efficiency was more than doubled. 
As illustrated in Figure 5, the transactivator construct bearing the 39 amino acid cleavage 
site induces a faster cell proliferation than the construct containing only 13 amino acids, 
maybe because a longer linker between LexA and Gal4AD allows a more optimal folding 
of the hybrid transcription factor. However, when the ACT4 CEN4-ARS1 plasmid 
encoding the HCMV protease is co-expressed with these two constructs, cell proliferation 
is comparable. Thus, whereas the cleavage of the transactivator bearing the short M-site 
reduced growth of 54%, the cleavage of the construct with the long M-site leaded to a 
growth reduction of 80%. Two hypothesis could explain the importance of using a longer 
cleavage site: i) more than P5-P5’ residues participate in the substrate recognition ii) the 
longer insert provides a favorable conformation to LexA-Me-Gal4AD substrate, where 
M-site is more accessible to HCMV protease catalytic site. To show that the cleavage 
occurs specifically at the M site and not in the LexA or Gal4AD domains, we substituted 
the alanine of the scissile bond with glutamic acid, a mutation known to prevent cleavage 
(Welch, McNally et al. 1993). As expected, this mutated substrate was not cleaved by the 
protease. 
In conclusion, several optimization steps were necessary to obtain a satisfying 
read-out to monitor HCMV protease activity. The choice of the protease domain, of the 
reporter strain, of the medium composition and of the cleavage site sequence were crucial 
to create a sufficient ratio between the density of cells expressing substrate alone and the 
density of cells co-expressing the protease. Figure 6 illustrates the growth curves of these 
two types of cells inoculated in selective medium containing 10% glycerol and 10 mM 3-
AT, at a start OD600 of 0.01.  
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3. Discussion 
 
This Part I of my PhD thesis describes the elaboration of a growth selection system that 
monitors human cytomegalovirus protease activity. This yeast system, inspired of 
previously described cell-based assays (Dasmahapatra, DiDomenico et al. 1992; Lawler 
and Snyder 1999), is based on the protease-mediated inactivation of a transcription factor 
that drives the expression of the HIS3 reporter gene. Cells expressing the protease exhibit 
a slow growth phenotype, and the inhibition of protease activity by small molecules is 
expected to stimulated cell proliferation. Thus, the assay developed here has a positive 
read-out, which should avoid the selection of toxic compounds because they inhibit cell 
proliferation per se. This should reduce the number of false positives that would show up 
in an assay with a negative readout. 
As described in the Result section, the optimization of this yeast assay monitoring 
HCMV protease was a long process. The protease activity was difficult to display 
prominently, mainly because of its low catalytic efficiency and of its characteristic of 
obligate dimer with high dissociation constant (8 µM Kd) (Margosiak, Vanderpool et al. 
1996). Thus, we assume that proteases with higher catalytic efficiency would be easier to 
address in a similar yeast assay. This is indeed the case, at least for the coxsackievirus 
(CV) protease 3C. In parallel to the development of the reporter system for the HCMV 
protease we elaborated a similar system for the CV protease 3C, which is an enzyme 
affiliated to the chymotrypsin-like proteases (Sarkany and Polgar 2003). In our first 
attempt of expressing protease 3C, protease activity produced a 10 folds reduction of cell 
proliferation (data not shown). No artifice was necessary to improve either the protease 
catalytic efficiency or the assay read-out. 
Once that all parameters of the HCMV protease screening assay were established 
we could easily adapt the system for other herpesviral proteases. As already mentioned in 
the introduction, herpesviral proteases are highly homologous and rely on the same 
mechanism of action (Waxman and Darke 2000). We expressed in our system the herpes 
simplex virus 1 (HSV-1) protease and the varicella-zoster virus (VZV) protease, 
modifying no parameter except of course that we inserted the respective M-sites between 
LexA and Gal4AD. Interestingly, HSV-1 protease, which has a low catalytic efficiency 
(38 s-1 M-1 vs 404 s-1 M-1 for HCMV protease) (Waxman and Darke 2000), was also less 
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efficient in cleaving the LexA-MHSVp-Gal4AD substrate than the HCMV protease to 
cleave its own substrate. In contrast, at a similar expression level VZV protease was 
much more active than HCMV protease (data not shown). I could not find any indication 
of catalytic efficiency for VZV protease in the literature, but I would deduce from our 
experiments that its kcat/Km is superior to 404 s-1 M-1. 
The yeast reporter gene assay described in this Part I is configured to detect 
downstream transcriptional consequences of HCMV protease activity and inhibition. The 
read-out - cell proliferation - is simple, and the use of a reporter system provides an 
amplified signal. However, like all reporter gene assays, also this one is subject to non-
specific interference by compounds that do not act directly on the protease but target 
intermediary signaling proteins of the HIS3 pathway. Such compounds could for example 
prevent the LexA dimerization or its binding to the regulatory promoter region, inhibit 
HIS3 transcription or translation, block His3p enzyme. In order to reduce the number of 
false positives, I developed an alternative assay, in which the reporter protein inactivated 
by the protease would be directly acting on the read-out system, thus skipping the steps of 
gene expression. This system is described in the second part of this thesis. 
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5. Figures  
 
 
 
 
Figure 1. Schematic model of the assay.  
A. The intact transcription factor binds to the GAL4 UAS and directs HIS3 reporter 
transcription. B. In the presence of an active protease, the transcription factor is cleaved 
and functionally inactive. GAL4 BD: GAL4 binding domain (1-147); GAL4 AD: GAL4 
activating domain (763-881); GAL4 UAS: GAL4 upstream activating sequence; 
GGVVNASCRLAGG: CMV protease consensus cleavage sequence. 
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Figure 2. Assemblin activity, but not pPR activity is detected in YDE172 strain, and β-
galactosidase assay is more sensitive than growth assay.  
Plasmids expressing the Gal4BD-M-Gal4AD substrate or an empty plasmid and the 29 
kDa mature HCMV protease (=assemblin), the 75 kDa protease precursor or an empty 
plasmid were co-transformed in YDE172 strain, as indicated. A. A liquid β-galactosidase 
assay was performed. B. Cells were diluted to a start OD600 0.03 and grown in selective –
His –Ura -Trp medium containing 30 mM 3-AT and OD595 was measured after 24 h.  
A 
B 
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Figure 3. HCMV protease activity is better detected in VCY3 strain.  
VCY3 strain was transformed with the LexA-M-Gal4AD substrate or en empty plasmid 
and the active or inactive HCMV protease, or an empty plasmid, as indicated. Cells were 
diluted to a start OD600 0.01 and grown in selective –His –Ura -Trp medium containing 
10 mM 3-AT and OD595 was measured after 24 h. 
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Figure 4. 10% glycerol promotes HCMV protease activity in VCY3 strain.  
LexA-M-Gal4AD substrate and the HCMV protease or an empty plasmid were 
transformed in VCY3, as indicated. Cells were diluted to a start OD600 0.01 and grown in 
selective –His -Ura -Trp medium containing 30 mM 3-AT, in presence or in absence of 
10% glycerol. OD595 was measured after 36 h. 
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Figure 5. Cleavage is site-specific and more efficient with a long recognition sequence. 
Plasmids expressing LexA-M-Gal4AD, LexA-Me-Gal4AD and LexA-Me*-Gal4AD 
substrates were co-transformed with plasmid expressing HCMV protease or with an 
empty plasmid in VCY3, as indicated. Cells were diluted to a start OD600 0.01 and grown 
in selective –His –Ura -Trp medium containing 10 mM 3-AT and 10% glycerol. OD595 
was measured after 32 h. 
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Figure 6. At the final conditions described below, cells expressing HCMV protease 
proliferate 4 times slower than cells expressing the LexA-Me-Gal4AD substrate alone.  
Plasmid expressing the LexA-Me-Gal4AD was co-transformed with plasmid expressing 
the HCMV protease or with an empty plasmid in VCY3, as indicated. Cells were diluted 
to a start OD600 0.01 and grown in selective –His –Ura -Trp medium containing 10 mM 
3-AT, 10% glycerol and 1% DMSO. OD595 was measured at the indicated time points. 
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3.2  Part II 
 
Novel Yeast Cell-based Assay to Screen for Inhibitors of Human 
Cytomegalovirus Protease in a High-Throughput Format 
 
 
Trp1-M system 
 
 
Abstract 
The protease encoded by the human cytomegalovirus (HCMV) is an attractive target for 
antiviral drug development because of its essential function in viral replication. We 
describe here a cellular assay in the yeast Saccharomyces cerevisiae for the identification 
of small molecule inhibitors of HCMV protease by conditional growth in selective 
medium. In this system, the protease cleavage sequence is inserted into the N-(5’-
phosphoribosyl)-anthranilate isomerase (Trp1p), a yeast protein essential for cell 
proliferation in the absence of tryptophan. Co-expression of HCMV protease with the 
engineered Trp1p substrate in yeast cells results in site-specific cleavage and functional 
inactivation of the Trp1p enzyme, thereby leading to an arrest of cell proliferation. This 
growth arrest can be suppressed by the addition of validated HCMV protease inhibitors. 
The growth selection system presented here provides the basis for a high-throughput 
screen to identify HCMV protease inhibitors that are active in eukaryotic cells. 
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The protease encoded by the human cytomegalovirus (HCMV) is an attractive target for antiviral drug
development because of its essential function in viral replication. We describe here a cellular assay in the yeast
Saccharomyces cerevisiae for the identification of small molecule inhibitors of HCMV protease by conditional
growth in selective medium. In this system, the protease cleavage sequence is inserted into the N-(5-phos-
phoribosyl)anthranilate isomerase (Trp1p), a yeast protein essential for cell proliferation in the absence of
tryptophan. Coexpression of HCMV protease with the engineered Trp1p substrate in yeast cells results in
site-specific cleavage and functional inactivation of the Trp1p enzyme, thereby leading to an arrest of cell
proliferation. This growth arrest can be suppressed by the addition of validated HCMV protease inhibitors.
The growth selection system presented here provides the basis for a high-throughput screen to identify HCMV
protease inhibitors that are active in eukaryotic cells.
Herpesviruses are widely present in nature and afflict many
species throughout the animal kingdom (14). The most fre-
quent human infection is caused by the human cytomegalovi-
rus (HCMV), affecting up to 80% of the general population.
This highly prevalent member of the herpesvirus family is re-
sponsible for opportunistic infections in immunocompromised
individuals, notably AIDS patients and organ transplant recip-
ients (for reviews, see references 9 and 29). Antiviral agents
currently licensed for the treatment of HCMV infections in-
clude ganciclovir and its orally bioavailable prodrug valganci-
clovir as well as foscarnet, cidofovir, and fomivirsen (9). All
these drugs are nucleoside analogues that ultimately target,
either directly or indirectly, the viral DNA polymerase. The
only exception is fomivirsen, an antisense oligonucleotide ap-
proved for HCMV retinitis that blocks translation of HCMV
immediate-early mRNA. Unfortunately for the patients, the
clinical usefulness of these drugs is limited: they exhibit toxic
side effects, including bone marrow toxicity and nephrotoxicity,
and they need to be injected either intravenously or intraocu-
larly (9). Moreover, HCMV strains with reduced susceptibility
resulting from chronic antiviral treatment are becoming more
and more frequent. Thus, improved alternative drugs with
novel mechanisms of action are needed for treating HCMV
infections.
Herpesviruses encode a serine protease that cleaves the as-
sembly protein precursor, a major component of the interme-
diate capsid (reviewed in reference 23). Studies with herpes
simplex virus type 1 protease, a close homologue of HCMV
protease, showed that viral DNA cannot be packaged into
virions without this cleavage, resulting in an empty nucleocap-
sid (17, 32). HCMV protease is expressed as a 708-amino-acid
precursor encoded by the UL80 open reading frame. Autocat-
alytic cleavage is observed at two consensus sequences called
maturational (M) and release (R) sites (23). M-site cleavage
removes a 6-kDa C-terminal tail, which mediates interaction
with the major capsid protein at the earliest stage of capsid
assembly. Cleavage at the R-site releases the N-terminal 28-
kDa proteolytic domain. Enzymatic in vitro assays with short
peptide substrates demonstrated a 10-fold increase in the
kcat/Km value for an M-site peptide substrate over that for an
R-site substrate (37).
Four different groups elucidated the X-ray crystallographic
structure of HCMV protease in 1996 (8, 33, 36, 38). These
studies have unequivocally confirmed the status of this enzyme
as a serine protease with a unique catalytic triad. Instead of the
His-Ser-Asp/Glu residues present in the active site of classical
serine proteases, HCMV protease contains an unusual His
residue at the third position. Moreover, only the dimeric form
is active, which sets it further apart from other serine proteases
(28). The two active sites are well separated on opposite faces
of the dimer and act in an independent manner (4). The fact
that the protease is essential for the propagation of the virus
and that it markedly differs from mammalian serine proteases
makes this enzyme an attractive therapeutic target.
Though peptidomimetic drug design delivered a number of
HCMV protease inhibitors with good in vitro potency in the
submicromolar range, e.g., translactams (5) and 2-substituted
benzoxazinones (1), their activity in cell culture remained lim-
ited. In addition, high-throughput screening (HTS) campaigns
in the industry, based on enzymatic in vitro assays, did not lead
to the identification of hits with good activity in cell culture
assays. Remarkably, very few reports describe the investigation
of HCMV protease activity in a cellular environment (26, 41),
and to our knowledge, no cell-based HTS has been performed
so far. More efforts should be invested in such cellular assays,
since they not only allow for screening in a natural cellular
environment but also directly exclude compounds that are un-
stable or toxic or that cannot penetrate biological membranes.
Thus, appropriate cell-based assays can accelerate the drug
discovery process (for reviews, see references 2 and 3).
In an effort to select for HCMV protease inhibitors in an in
vivo environment, we have established a target-specific HTS
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system in Saccharomyces cerevisiae that detects protease activ-
ity by conditional growth in selective medium. In a proof-of-
principle experiment, we show that the application of known
HCMV protease inhibitors results in a concentration-depen-
dent stimulation of cell proliferation.
MATERIALS AND METHODS
Yeast strains. The genes encoding the three major ABC transporter proteins
Pdr5p, Snq2p, and Yor1p were deleted in the S. cerevisiae JPY5 strain (MAT
ura3-52 his3200 leu21 trp163 lys2385) to generate the RLY07 strain (MAT
ura3-52 his3200 leu21 trp163 lys2385 pdr5 snq2 yor1). All recombinant
proteins described in this study were expressed in RLY07 cells.
Recombinant plasmids. The S. cerevisiae TRP1 gene was amplified by PCR
from the plasmid YCplac22 (20). All TRP1-M constructs generated hereupon
were subcloned via unique XbaI and SalI restriction sites in the CEN4-ARS1
plasmid pMH4. pMH4 carries a LEU2 auxotrophic marker and expresses sub-
cloned TRP1-M constructs under the control of a 5 truncated version of the
ADH promoter and the GAL11 terminator. The HCMV protease cleavage se-
quence GGVVNA2SCRLAGG, derived from the M site of the 75-kDa pro-
tease precursor, was flanked with unique NcoI and NotI sites and inserted by
PCR directly to the C-terminal end of amino acid residues 49, 102, 132, 165, and
194 of the Trp1 protein. This generated a plasmid series encoding the recombi-
nant proteins Trp149-M, Trp1102-M, Trp1132-M, Trp1165-M, and Trp1194-M. In
order to generate Trp1194-Me (for Trp1194-M elongated), the 13-amino-acid
cleavage sequence was replaced (via NcoI and NotI sites) by an extended M-type
sequence consisting of 39 amino acids (see Fig. 3). For Western blotting, hem-
agglutinin (HA) epitope tags were added to both termini of the Trp1194-Me
construct. The HCMV protease gene encoding amino acids 1 to 256 of the
708-amino-acid protease precursor was obtained by PCR from HCMV-infected
MRC5 human cells and subcloned via unique XbaI and NotI sites in pMH51, a
CEN4-ARS1 plasmid with a URA3 selection marker and a full-length (100%)
GAL1 promoter. In the experiment for which results are shown in Fig. 4, the
HCMV protease gene was subcloned in a plasmid series with distinct GAL1
promoters that express the protease with 71%, 46%, and 16% protein production
levels relative to the original 100% GAL1 promoter. The GAL1 promoter con-
tains four different pseudopalindromic binding sites for the transcription factor
Gal4p. Liang et al. have shown that modifications in the number and type of
Gal4p binding sites modulate transcription of a downstream cloned reporter
gene (27). We have differentially deleted those binding modules and validated
promoter strength with a downstream cloned lacZ reporter gene (above 71%,
46%, and 16% protein production levels).
Yeast media and transformation. All media were prepared according to Burke
et al. (7). Transformation of yeast cells was performed following the lithium
acetate method (19).
Spotting assay. RLY07 cells transformed with the different TRP1-M constructs
were inoculated in 3 ml synthetic dropout (SD) glucose medium lacking Leu
(Leu) and grown to an optical density at 595 nm (OD595) of 1 to reach an
exponential growth phase. Cultures were hereupon washed with 5 ml H2O,
resuspended in Leu Trp SD glucose medium and diluted to 106 cells/ml. Ten
microliters of serially diluted culture was spotted on nonselective (Leu) and
selective (Leu Trp) glucose SD plates and incubated at 30°C for 3 days.
Liquid growth assays. RLY07 cells transformed with the different TRP1-M
constructs and the HCMV protease gene were inoculated in 3 ml Leu Ura
galactose SD medium and grown at 30°C to an OD595 of 1. They were then
washed with 5 ml H2O and resuspended in Leu Ura Trp galactose SD
medium supplemented with 10% glycerol (growth selection medium). It is likely
to assume that glycerol promotes HCMV protease dimerization and subsequent
proteolytic activity, as it has been shown in in vitro assays (28). In yeast, glycerol
is taken up by a proton symport mechanism (13). Liquid growth assays were
started at an inoculation OD595 of 0.01 in growth selection medium in 96-well
microtiter plates in a volume of 150 l per well. Cultures were incubated at 30°C
without shaking. At defined time points (as specified in figure legends), plates
were shaken at 1,000 rpm for 1 min to completely resuspend cells, and cell
density was measured at 595 nm on a Tecan GENios reader (Ma¨nnedorf, Swit-
zerland). HCMV protease inhibitors BI31 and BI36 (Boeringher Ingelheim,
Que´bec) were dissolved in dimethyl sulfoxide and added to the cultures directly
at the beginning of the growth assay; final dimethyl sulfoxide concentration was
1%.
Western blot analysis. Yeast whole-cell extracts were prepared as described by
Burke et al. (7). Proteins were separated by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis, and Western blot analysis was performed according to
standard procedures. An anti-HA monoclonal antibody from Sigma (clone 3F10)
was used at a concentration of 30 ng/ml to detect expression of Trp1194-Me.
RESULTS
A cell-based system to detect protease activity. In the
present work, we describe a cell growth selection system in the
yeast S. cerevisiae that (i) can detect and characterize HCMV
protease activity and (ii) is applicable to screen for HCMV
protease inhibitors in a high-throughput format. To establish
this system, we inserted an HCMV protease cleavage site into
a yeast protein that is conditionally essential for cell prolifer-
ation. This protein was chosen from the auxotrophic growth
markers, considering that most laboratory strains are already
deleted for these genes and that therefore, such a system could
be applied in almost any genetic background. Since the N-(5-
phosphoribosyl)anthranilate isomerase (Trp1p) enzyme has
been intensively studied (10, 11, 22, 24) and its three-dimen-
sional structure has been determined for different organisms,
we have chosen this member of the tryptophan synthesis path-
way as a substrate for HCMV protease.
Thus, in our setup, such an engineered Trp1 enzyme should
be cleaved and subsequently inactivated by HCMV protease,
resulting in a reduced growth in selective medium lacking
tryptophan.
Insertion of the HCMV protease cleavage sequence at five
different locations in Trp1p. Two conditions are critical for
appropriate operation of the above-described system. (i) In-
sertion of the HCMV protease cleavage sequence must pre-
serve Trp1 function in the tryptophan biosynthesis pathway.
(ii) On the other hand, cleavage at the inserted sequence must
result in functional inactivation of the Trp1 enzyme.
The Trp1 enzyme is a member of the prominent class of
proteins that fold into a (/)8 barrel, which is the most com-
monly occurring fold among enzymes (12) (Fig. 1). The S.
cerevisiae Trp1p structure has not yet been determined, but
amino acid sequence alignments with the N-(5-phosphoribo-
syl)anthranilate isomerase from Escherichia coli and Thermo-
toga maritima provide us with a reliable model. S. cerevisiae
Trp1p shares 28% identical amino acids with E. coli Trp1p and
FIG. 1. Modeled structure of the S. cerevisiae N-(5-phosphoribo-
syl)anthranilate isomerase Trp1p. Residues preceding the inserted M-
cleavage sequences are indicated in blue.
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33% with T. maritima Trp1p. Alignment and modeling for S.
cerevisiae Trp1p was performed with the SWISS-MODEL pro-
tein modeling server (http://swissmodel.expasy.org/repository/)
(21, 35).
To determine suitable sites for insertion of the cleavage
sequence, several constructs were designed. Since turn se-
quences are in general highly mutable in (/)8 barrels, five
insertion sites were chosen that are located in such turns be-
tween an -helix and a -sheet, after amino acids Asp49,
Asp102, Ala132, Gly165, and Gly194 (Fig. 1A). Respective con-
structs will therefore be referred to as Trp149-M, Trp1102-M,
Trp1132-M, Trp1165-M, and Trp1194-M. The inserted sequence
consists of 13 amino acids derived from the M site of the
75-kDa protease precursor (see Fig. 3A, sequence a).
In order to evaluate the functionality of the Trp149-M,
Trp1102-M, Trp1132-M, Trp1165-M, and Trp1194-M fusion pro-
teins, a spotting assay was performed (Fig. 2A). RLY07 cells
were transformed with these constructs, and their ability to
proliferate was assessed on selective plates lacking tryptophan.
For Trp1132-M-, Trp1165-M-, and Trp1194-M-expressing cells,
growth was indistinguishable from that of cells expressing wild-
type Trp1p, indicating that M-site insertion did not interfere
with the functionality of the enzyme. In contrast, Trp149-M and
Trp1102-M constructs produced nonfunctional enzymes, as
demonstrated by likewise-transformed cells unable to grow on
selective plates (Fig. 2A).
Sequence-specific cleavage of Trp1194-M by HCMV protease
in yeast. We next investigated whether the three functional
Trp1-M proteins are cleaved and inactivated by HCMV pro-
tease. Trp1132-M, Trp1165-M, and Trp1194-M were coexpressed
with the viral protease in the RLY07 strain, and cell prolifer-
ation was assayed by measuring OD595 of transformed cells
cultured in growth selection medium (Fig. 2B). After 36 h, cells
coexpressing Trp1194-M with the protease exhibited a growth
reduction of 35% compared to control cells that contained an
empty vector instead of the protease-expressing plasmid, indi-
cating that cleavage between helix 7 and strand 8 reduces
activity of the Trp1 enzyme. Interestingly, this region is situ-
ated close to the phosphate binding site of the anthranilate
substrate. Crystallographic studies have shown that the two
neighboring loops between 7 and 7 and between 8 and 8
are important for binding of the phosphate ion (40). Cleavage
in this region might cause structural changes, thus preventing
binding of the substrate. As opposed to Trp1194-M cells,
Trp1132-M- as well as Trp1165-M-expressing cells did not show
growth reduction upon coexpressing HCMV protease (Fig.
2B). Thus, the latter two engineered Trp1 substrates were
either not cleaved or, alternatively, cleavage occurred but the
separated fragments still formed an active enzyme.
To improve cleavage frequency at the M site of the
Trp1194-M substrate, the 13-amino-acid target sequence was
replaced by a longer sequence consisting of 39 amino acids
(Fig. 3A, sequence b). Cells expressing the modified
Trp1194-Me together with the active protease showed 85%
reduction of cell proliferation compared to the 35% reduction
with the original, shorter cleavage site (Fig. 3B). This indicates
that the extended recognition site is more efficiently cleaved by
the protease.
The HCMV protease has been shown to hydrolyze both the
M site and R site of the protease precursor between an alanine
and a serine (6). To demonstrate site-specific cleavage of the
Trp1194-Me substrate, we replaced the alanine of the scissile
bond with glutamic acid (Fig. 3A, sequence c), a mutation
known to prevent cleavage (39). As expected, the proliferation
of cells coexpressing the Trp1194-Me(A3E) mutant with
HCMV protease was comparable to the proliferation of cells
expressing Trp1194-Me alone, providing evidence that the
Trp1194-Me substrate is cleaved in a sequence-specific manner
at the scissile bond (Fig. 3B). A further control experiment was
performed by using an enzymatically inactive version of
HCMV protease harboring the S132A mutation at the active-
site serine (8). As shown in Fig. 3B, this mutant was not able to
cleave the Trp1194-Me substrate.
To demonstrate actual cleavage of the substrate in yeast,
Trp1194-Me was tagged with an HA epitope and analyzed by
Western blotting. The full-length substrate migrates at the
level of 33-kDa proteins in a sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis assay (Fig. 3C, lane 1). Coexpres-
sion of active HCMV protease (Fig. 3C, lane 2) causes the
disappearance of the full-length substrate upon Western blot
analysis of the respective yeast extracts. However, no cleaved
FIG. 2. Functional tests of the five engineered Trp1p constructs.
(A) Serial dilutions of RLY07 cells transformed with wild-type (wt)
Trp1p (positive control), empty vector (negative control), Trp149-M,
Trp1102-M, Trp1132-M, Trp1165-M, or Trp1194-M were spotted on se-
lective Trp plates and incubated 3 days at 30°C. (B) Wild-type Trp1p,
Trp1132-M, Trp1165-M, and Trp1194-M constructs, cotransformed in
RLY07 either with an empty vector (dashed bars) or with active
HCMV protease (black bars) were grown in selective Trp medium
for 35 h; cell density was measured at 595 nm. Data are expressed as
means from three independent experiments  standard deviations.
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fragments could be detected. We suppose that they are either
degraded or below the detection threshold of the Western blot.
Lane 3 of Fig. 3C shows that the inactive viral protease does
not cleave Trp1194-Me since the full-length substrate band
does not disappear. Lane 4 shows that the active protease has
no effect on the point-mutated Trp1194-Me(A3E) substrate.
Taken together, the above-described experiments demon-
strate that the Trp1194-Me substrate is cleaved in a sequence-
specific manner by HCMV protease and that this cleavage
results in a slow-growth phenotype.
Modulation of HCMV protease expression level correlates
with distinct changes in cell proliferation. A prerequisite for a
successful HTS is that even only partial inhibition of the pro-
tease can be detected in the assay. We were therefore inter-
ested to find out whether different concentrations of intracel-
lular active protease result in distinguishable and selectable
levels of growth rate on the HTS read-out. In the experiments
described above, HCMV protease was expressed from the full-
length GAL1 promoter (100% activity). To express the pro-
tease at distinct lower levels, thus mimicking partial protease
inhibition by a small molecule in a screening experiment, the
protease was subcloned on a GAL1 vector series, with discrete
protein production levels of 71%, 46%, and 16% compared to
the original 100% promoter. These plasmids were cotrans-
formed with the Trp1194-Me substrate in RLY07 cells, and cell
growth was measured after 36 h at OD595. Figure 4 shows that
a gradual decrease of promoter strength, and thus of intracel-
lular protease activity, is inversely proportional to cell prolif-
eration. For example, a reduction of 29% of protease expres-
sion (from the 100% promoter to the 71% promoter) resulted
in a 53% stimulation of cell proliferation. Likewise, a reduction
of 54% of protease expression caused a stimulation of 138%.
Therefore, even weak inhibitors that cause only a partial re-
duction of HCMV protease activity should be detectable in our
system.
Two validated HCMV protease inhibitors stimulate cell pro-
liferation in a screening assay format. The assay described
above was developed to identify cell-permeable small molecule
inhibitors of HCMV protease in high-throughput screening
experiments. We have already shown that the system is able to
distinguish different levels of intracellular protease activity. In
order to assess sensitivity of the selection system towards small
molecules, the two validated HCMV protease inhibitors BI31
and BI36 of Boehringer Ingelheim were applied (42). BI31 and
BI36 show 50% inhibitory concentration values of 1.7 and 0.5
M in an enzymatic in vitro assay and inhibit viral replication
in cell culture with 50% effective concentration (EC50) values
of 95 and 78 M, respectively (42). Both compounds are based
on a 4-thioalkyl -lactam scaffold. Lactam derivatives have
FIG. 3. Sequence-specific cleavage of the Trp1194-Me substrate by
the HCMV protease. (A) HCMV protease cleavage sequences in-
serted C terminal to G194 of Trp1p. a) 13 residues (short) with the M
site; b) 39 residues (long) with the M site; c) long M-site sequence with
the point mutation A3E at the scissile bond. (B) RLY07 cells were
cotransformed with the different Trp1194-M substrates and a plasmid
expressing either active or inactive (active-site point mutation S132A)
HCMV protease, as indicated. Cells were grown in selective Trp
medium, and OD595 was measured after 38 h. Data are expressed as
means from three independent experiments  standard deviations.
(C) Western blot analysis of Trp1194-Me cleavage by HCMV protease.
The uncleaved 33-kDa Trp1194-Me substrate, which carries HA tags at
both termini, is detected by immunoblotting with an anti-HA antibody.
Protein extracts were made from transformed RLY07 cells expressing
Trp1194-M (lane 1), Trp1194-M and active HCMV protease (lane 2),
Trp1194-M and inactive HCMV protease (lane 3), Trp1194-Me(A3E)
and active HCMV protease (lane 4), and empty vectors (negative
control) (lane 5). The calmodulin antibody was used as an internal
control for protein amount.
FIG. 4. A gradual decrease of HCMV protease expression corre-
lates with distinct stimulation of cell proliferation. In the first four
columns, RLY07 cells were cotransformed with Trp1194-Me and with
active HCMV protease expressed from a GAL1 promoter series (see
Materials and Methods for detailed information). The last column
shows cell growth mediated by the inactive protease. Cell densities
were monitored after 30 h by measuring OD595. Data are expressed as
means from three independent experiments  standard deviations.
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initially been published as inhibitors of classical serine pro-
teases, such as human leukocyte elastase (15). Further devel-
opment of such scaffolds by rational design delivered inhibitors
specific for HCMV protease (42).
RLY07 cells coexpressing the Trp1194-Me substrate and
HCMV protease were incubated with various concentrations
of BI31 and BI36 in a 96-well microtiter plate and cultivated
under selective conditions at 30°C for 44 and 28 h, respectively.
Figure 5A shows that increasing concentrations of both BI31
and BI36 in cells expressing the active protease correlate with
increasing cell proliferation. The calculated EC50 of 31 M for
BI36 suggests that the yeast-based assay exhibits the same
sensitivity as that of a mammalian cellular assay, at least for
this class of compounds (42). At BI36 concentrations of 	100
M, HCMV protease was strongly inhibited, as evidenced by
proliferation rates similar to those of cells expressing the in-
active protease. Though BI31 also restored cell growth in a
concentration-dependent manner, stimulation was not as pro-
nounced as with BI36 due to cellular toxicity of this compound.
This toxicity is also shown by the fact that increasing concen-
trations of BI31 in RLY07 cells expressing the inactive (active-
site mutated S132A) HCMV protease caused a gradual de-
crease of cell proliferation. Importantly, despite this toxicity,
BI31 still stimulated growth of cells expressing the active pro-
tease. For example, at 50 M cell density is multiplied by a
factor 4 despite 25% toxicity. This suggests that in an HTS,
compounds will be scored as positives even if they exert some
intrinsic toxicity.
Inhibition of HCMV protease activity in yeast by BI36 was
also addressed by Western blot analysis (Fig. 5B). As already
shown in Fig. 3C, a 33-kDa band corresponding to the un-
cleaved full-length Trp1194-Me substrate can be detected in
cells coexpressing the Trp substrate with the inactive (S132A)
protease. In cells cotransformed with the active protease in-
stead of the inactive version, disappearance of the 33-kDa
band can be observed. Importantly, the addition of 100 M
BI36 to the growth selection medium of those cells almost
completely prevented cleavage of the substrate (Fig. 5B).
When using lower concentrations of BI36 (10 M), the full-
length substrate band disappears again, suggesting that at con-
centrations well below the calculated EC50 of 31 M in yeast,
only a small percentage of protease activity is inhibited.
In summary, we have shown that two well-validated active-
site inhibitors of HCMV protease cause a concentration-de-
pendent stimulation of cell growth in our yeast assay. Impor-
tantly, sensitivity of the yeast system towards these two
compounds is comparable to the sensitivity of a mammalian
cell-based assay. The calculated Z factor values of 0.85 for 50
M BI36 and 0.75 for 50 M BI31 clearly demonstrate the
suitability of this bioassay for high-throughput applications.
DISCUSSION
The frequent emergence of cytomegalovirus strains resistant
against classical antiviral agents, which all directly or indirectly
target viral DNA polymerase, spurred the search for alterna-
tive therapeutic targets of the virus (reviewed in reference 29).
The cytomegalovirus protease, or assemblin, has gained much
attention as a target due to the unique serine protease fold and
catalytic triad that is expected to facilitate the design of virus-
specific inhibitors. Though past screening campaigns have cul-
minated in the identification of inhibitors with nanomolar ac-
tivities in enzymatic in vitro assays, their activity in cell-based
assays was limited in most cases. Examples include benzoxazi-
nones (16), lactams (5, 18), and the highly toxic enedione
derivatives (30). To our knowledge, no cell-based HTS on
FIG. 5. Validated HCMV protease inhibitors BI31 (upper panel)
and BI36 (lower panel) stimulate cell proliferation in a concentration-
dependent manner. (A) RLY07 cells expressing Trp1194-Me and active
HCMV protease (triangles) or Trp1194-Me and inactive protease
(squares) were cultivated either in the absence (0) or presence of
increasing concentrations of BI31 and BI36. Cells were grown in
150-l cultures in a 96-well microplate for 44 h (BI31) and 28 h (BI36)
before OD595 was measured. Data are expressed as means from three
independent experiments  standard deviations. (B) Western blot
analysis with HA antibody showing that application of BI36 prevents
cleavage of the Trp1194-Me substrate by HCMV protease. RLY07 cells
were transformed with Trp1194-Me and inactive protease (positive
control), Trp1194-Me and active protease, or Trp1194-Me with active
protease in the presence of distinct concentrations of BI36, as indi-
cated. RLY07 cells containing two empty plasmids were used as a
negative control. The calmodulin antibody served as an internal con-
trol for protein amount. DMSO, dimethyl sulfoxide.
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herpesviral proteases has so far been performed successfully.
Compared to in vitro assays, cellular systems allow for the
screening of the therapeutic target in its natural configuration
within the cell. In addition, they select for compounds that are
stable within a metabolic environment, that are able to pene-
trate biological membranes, and that show no or only limited
toxic effects on the cell (for reviews, see references 2 and 3).
Therefore, appropriate cellular systems potentially accelerate
the drug discovery process.
We have established a cellular assay in the yeast S. cerevisiae
that detects HCMV protease activity and that enables screen-
ing for small molecule protease inhibitors with a positive
growth read-out. Yeast provides a eukaryotic environment in a
single cell with a high degree of conserved basic molecular
mechanisms with mammalian cells. In addition, yeast is inex-
pensive to propagate and can be easily genetically engineered.
For establishing the growth selection system described here,
a 39-amino-acid HCMV protease cleavage sequence derived
from the M site of the 75-kDa protease precursor was inserted
into the phosphoribosylanthranilate isomerase, a yeast enzyme
involved in the biosynthesis of tryptophan and therefore essen-
tial for cell proliferation in the absence of tryptophan. Coex-
pression of HCMV protease with this engineered substrate
caused sequence-specific cleavage at the M site, resulting in
growth arrest (Fig. 3B). Importantly, the addition of validated
cell-active -lactam inhibitors restored cell proliferation in a
concentration-dependent manner (Fig. 5B). Since yeast en-
codes a pleiotrophic drug resistance network with a variety of
ABC transporters that efficiently clear small molecules within
the cell, we sensitized the strain by deleting the three major
drug efflux pumps Pdr5p, Snq2p, and Yor1p. In such a setup,
the yeast system shows a sensitivity towards small molecules
similar to that shown in a mammalian cellular assay, at least for
the -lactam inhibitors tested, with a calculated EC50 of 31 M
in the yeast assay versus 78 M in a mammalian plaque reduc-
tion assay (42).
HCMV protease has been shown to be active as a dimer
(28). Remarkably, enzymatic in vitro assays require high con-
centrations of dimerization-promoting agents, such as anti-
chaotropic salts and glycerol, that dramatically increase the
kcat/Km value to obtain reasonable turnover rates of the en-
zyme (25, 28). The fact that in our cellular assay a gradual
increase of glycerol concentration correlates inversely with cell
proliferation (data not shown) underscores the hypothesis that
HCMV protease is also a dimer in yeast. This is confirmed by
the observation that the point mutation L221A completely
inactivates HCMV protease in yeast (data not shown). It has
been demonstrated for Kaposi’s sarcoma-associated herpesvi-
rus protease that mutating the homologous residue L196 to an
alanine abrogates protease activity by preventing dimerization
(31).
It is a subject of debate whether the 29-kDa assemblin or the
75-kDa protease precursor is the physiologically relevant pro-
tease responsible for capsid maturation and therefore the ap-
propriate therapeutic target. While all enzymatic HTS has
been performed with the 29-kDa domain, Robertson et al.
suggested the 75-kDa precursor to be the “real” target. Indeed,
transcomplementation studies with mutant herpes simplex vi-
rus type 1 viruses have shown that the proteolytic activity
essential for capsid maturation is provided by the full-length
precursor protein (34). We coexpressed Trp1194-Me with the
75-kDa protease precursor and observed a minor but statisti-
cally significant reduction in cell growth (data not shown). We
are currently investigating whether this proteolytic activity is
derived from the protease precursor per se or whether the
29-kDa assemblin, generated upon autocatalytic cleavage, is
responsible for cleavage of the Trp1 substrate.
Applicability of the above-described Trp1p-based yeast as-
say is not limited to HCMV protease and can be exploited for
other proteases. We have replaced the M site of the
Trp1194-Me substrate with a 13-amino-acid cleavage sequence
of the coxsackievirus 3C cysteine protease. Coexpression of the
likewise-engineered Trp1 substrate with the 3C protease re-
sulted in an arrest of cell proliferation (data not shown). In a
proof-of-concept study, we have used the Trp1-M system as a
validation tool for hits identified in a high-throughput screen of
a 15,000-chemical-compound library. With this approach, we
have identified a number of compounds that also show activity
in a mammalian plaque reduction assay in the low-micromolar
range (unpublished data).
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3.3. Part III 
 
HTS and hit validation 
 
Abstract 
In order to identify HCMV protease inhibitors, the yeast-based Lex-M system (as 
described in Part I of this thesis) was optimized for high-throughput screening (HTS). An 
automated screening of a 15’000 small molecule library was performed at 50 µM final 
concentration. 67 compounds, which counteracted the growth inhibition caused by 
HCMV protease in a concentration-dependant way, were selected. These compounds 
were tested for inhibition of viral propagation in human cells by two different methods, 
i.e. ELISA and plaque reduction assay (PRA). Though several compounds showed 
activity in low micromolar IC50 range in both assays, potential effects of compound 
toxicity on virus proliferation could not be excluded. In order to test whether these 
selected compounds inhibited HCMV protease activity, we performed in vitro FRET 
assays and analyzed pAP substrate cleavage by electrophoresis and Trp1194-Me substrate 
cleavage by Western blotting. However, despite many efforts, we were not able to prove 
a direct HCMV protease inhibition by our compounds. 
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1. Material and Methods 
 
1.1. Yeast strains  
The VCY3 strain used for screening and the RLY07 strain used for compound testing in 
the Trp1-M system were described in Material and methods of Part I and Part II, 
respectively.  
 
1.2. Construction of plasmids 
Plasmids expressing the human cytomegalovirus protease (aa 1-256), the LexA-Me-
Gal4AD substrate and the Trp1194-Me substrate were described in Material and methods 
of Parts I and II.  
 
1.3. The chemical library 
The screening library is constituted of 15’000 compounds selected from the 
commercially available ChemDiv (www.chemdiv.com) library. These 15’000 compounds 
were chosen by means of a filtering approach called the Lipinski’s “rule-of-5” (Lipinski, 
Lombardo et al. 2001).  
 
1.4. Screening procedure 
The yeast strain VCY3 expressing HCMV protease (1-256) from the GAL1 promoter and 
the LexA-Me-Gal4AD substrate from the truncated ADH1 promoter was used for 
screening the 15’000 compound library. The screening was performed in a 96-well 
format at a final concentration of 50 µM. 80 wells per plate contained 1.5 µL of different 
test substances dissolved in DMSO at a concentration of 5 mM. As negative control for 
yeast growth, 8 wells per plate contained 1.5 µL DMSO. The remaining 8 wells 
contained 1.5 µL of 0.15% glucose as a positive control for yeast growth. Glucose 
represses expression of HCMV protease driven by the GAL1 promoter and therefore 
mimics the effect of a HCMV protease antagonist.  
The library was divided into 5 batches of 38 plates (batch 5 contained only 36 
plates). One batch was screened in 2 days. Yeast preculture was grown overnight in 
synthetic medium (-Leu/-Trp) containing 2% galactose. The next day, exponentially 
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growing cultures were washed once with water and diluted to an OD600 of 0.001 in 1 L –
His/-Leu/-Trp selective medium containing 2% galactose. 150 µL of the diluted cells 
were added to 96-well plates in a fully automated manner by a Tecan robot. To obtain a 
blank value (t=0), OD595 was measured directly after addition of yeast cells by a 
microtiter plate reader (GENios Reader, Tecan). The plates were then incubated at 30°C 
and after 30 s shaking OD595 was read after 24, 30 and 36 h. 
To evaluate the quality of the screening, the Z’ factor (Zhang, Chung et al. 1999) 
for each screening plate was calculated using the following equation: 
Z’ = 1 – 3 x (SDEVpositive control + SDEVnegative control)/(AVpositive control -  AVnegative control) 
(SDEV: standard deviation; AV: average) 
The Z’ factor is the most commonly used metric to define HTS assay quality. An assay 
with Z’=1 would be an ideal assay. In practice, assays with 1 > Z > 0.5 are considered as 
suitable for HTS.  
 
1.5. FRET HCMV protease assay 
Recombinant HCMV protease (assemblin) was purchased at BACHEM (H-2138). 
HCMV protease FRET substrates were also from BACHEM (I-1870 (Ac-tBu-Gly-tBu-
Gly-Asn(Me)2-Ala-7-AMC substrate (Bonneau, Plouffe et al. 1998)) and M-2450 (Abz-
tBu-Gly-tBu-Gly-Asn(Me)2-Ala↓Ser-Ser-Arg-Leu-Tyr(3-NO2)-Arg-OH substrate 
(Bonneau, Plouffe et al. 1998)).  
To perform the biochemical assay, the protease was diluted to a 2.5 µM stock 
solution in assay buffer (50 mM Tris/HCl pH8, 0.5 M Na2SO4, 50 mM NaCl, 0.1 mM 
EDTA, 1 mM DTT and 0.05% casein), and the substrates to a 1 mM stock solution in 
DMSO. Inhibitors were dissolved in DMSO as 20x solution. Assays were performed in 
25 µL reactions with 50 nM protease and 5 µM substrate. The enzymatic reactions were 
carried out in black, opaque polystyrene 384 well plates (Corning, # 3676). 1.25 µL of 
20x compound solution was distributed per well and mixed with 11,25 µL of 100 nM 
protease dissolved in assay buffer. The plate was then incubated 30 min at 30°C, and 12.5 
µL of 10 µM substrate solution was added. Progress curves were monitored at Ex 
360/Em 440 nm for the AMC substrate and Ex 312/Em 415 nm for the Abz substrate on a 
Tecan GENios Reader. Compounds were tested in triplicate, at concentrations where no 
precipitation, autofluorescence and quenching could be observed.  
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1.6. Cells 
Human embryonic lung fibroblasts (MRC5) and human embryonic kidney epithelial cells 
(HEK 293) were obtained from the American Type Culture Collection (CRL-1573 and 
CCL-171). MRC5 cells were grown in minimum essential medium Eagle (MEM, Gibco) 
supplemented with 2 mM L-glutamine and Earle’s BSS (1.5 g/L sodium bicarbonate), 0.1 
mM non-essential amino acids, 1 mM sodium pyruvate and 10 % fetal calf serum (FCS), 
and used between culture passages 18 and 21. HEK 293 were grown in Dulbecco’s 
modified Eagle Medium (DMEM, Gibco) supplemented with 5% FCS. Cell cultures were 
incubated at 37°C in a 5% CO2 atmosphere. 
 
1.7. Viruses  
HCMV (strain AD169, ATCC number VR-538) stocks were prepared by propagating the 
virus in a MRC5 cell culture. When 90-100% of the cells showed symptoms of infection, 
supernatant was removed, cells were trypsinized and collected in complete MEM + 5% 
FCS + 5% DMSO. This cell-associated inoculum was aliquoted and stored at –80°C.  
Coxsackievirus B3 (Strain Nancy, ATCC number VR-30) stocks were prepared 
by propagating the virus in a HEK 293 cell culture. When 90-100% of the cells were 
floating in the medium, the medium containing the non-adsorbing cells was collected and 
centrifuged 3 min at 800 rpm. Supernatant was removed and the cells were resuspended 
in a small volume of complete MEM + 2% FCS (about 10% of the previous volume) and 
transferred to Eppendorf tubes. After 3 freeze-thaw cycles, Eppendorf tubes were 
centrifuged for 5 min at 10’000 rpm at 4°C, and the supernatant containing free viruses 
was collected. 5% DMSO were added to the virus suspension, which was subsequently 
aliquoted and stored at –80°C. Infectivity of both virus stocks was determined by end 
point titration (Spearman and Kärber, 1912).  
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1.8. Antiviral ELISA assay 
1. Infection with HCMV: 
104 MRC5 cells were distributed per well in 96-well plates (NUNC, # 167008) in 
a volume of 100 µL of assay medium (complete MEM as defined above+ 5% 
FCS). For each compound concentration, 3 wells were infected with 100 PFU of 
HCMV diluted in 50 µL assay medium, and 1 control well received only 50 µL 
assay medium. Plates were then incubated at 37°C for 48 h. Compounds were 
diluted in assay medium at 4x the final concentration, and 50 µL were added per 
well. Ganciclovir at 4 µM (final concentration) was used as positive control, 
negative control cells were treated with DMSO. The plates were then incubated 
for further 5 days. 
 
2. Infection with CVB3: 
3 x 104 HEK 293 cells were seeded per well in 96-well plates in a volume of 100 
µL of assay medium (DMEM + 2% FCS) and infected with 100 PFU of CVB3 
resuspended in a volume of 50 µL assay medium. Compounds were added 
simultaneously to the virus suspension as described for HCMV and the plates 
were incubated for 24 h at 37°C. 
 
3. ELISA  
Medium was tipped from the plates and the cell monolayers were washed 1x by 
gentle immersion in phosphate buffered saline (PBS). PBS was then removed and 
the cells were fixed by addition of 100 µL of 1:1 mix of acetone and methanol for 
3 min. Following a further wash with PBS, plates were blocked with 100 µL of 
PBS containing 0.05% Tween 20 and 2% skimmed milk powder at 37°C for 30 
min. The plates were then washed 1x with PBS + 0.05% Tween 20, and 50 µL of 
anti-CMV antibody (mouse monoclonal antibody directed against gB late 
cytoplasmic antigen, ANAWA) diluted 1:500, or anti-CV antibody (mouse 
monoclonal antibody, Chemicon International) diluted 1:1000, was added to each 
well. After 2 h incubation at 37°C, plates were washed 3x with PBS/Tween, and 
50 µL of goat anti-mouse IgG antibody conjugated to horseradish peroxidase 
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(PIERCE) diluted 1:1’000 was added to the wells. The plates were incubated for 
another hour, washed thoroughly 5x and dried. 50 µL substrate solution (BM blue 
POD, Roche) was added per well, and color allowed to develop at room 
temperature. The reaction was stopped by the addition of 50 µL 1 M HCl, and the 
plates were read spectrophotometrically at a wavelength of 450 nm. 
The mean color development of triplicate infected wells at each compound 
concentration was calculated as a percentage of the mean adsorption of untreated, 
infected controls after both values had been adjusted for nonspecific background. 
These percentage inhibition values were plotted against compound concentration 
and the 50% inhibitory concentration (IC50) derived by regression analysis (graph 
prism). 
 
1.9. XTT assay 
The XTT assay was performed in parallel to the ELISA assay. Cell seeding and 
compound treatment were done as described for the ELISA assay, except that phenolred-
free media were used and that no virus suspension was added to the cells. An XTT 
(AppliChem, # 111072-31-2) working solution was prepared by adding 25 µM of PMS to 
1 mg/mL of XTT diluted in phenolred-free medium. 50 µL of this working solution was 
added to each well and OD450 was measured after 1 h. 
 
1.10. Plaque reduction assay (PRA) 
106 MRC5 cells were seeded in 5 cm diameter dishes with grid, in 4 mL of complete 
MEM + 10% FCS. 3 rectangles of 4 cm x 1 cm had been drawn on each dish to facilitate 
the counting of the plaques afterwards. After 24 h, confluent monolayers were infected 
during 2 h with 2 mL of HCMV (strain AD169) inoculum at an infectivity ratio of 400 
PFU/mL. Thereafter, unadsorbed viruses were removed from the plates and compounds 
diluted in complete MEM + 5%FCS were added. After 7 days of incubation at 37°C, cells 
were washed once with PBS, fixed with 10% formaldehyde and stained with 0.8% crystal 
violet (Sigma) prepared in 20% ethanol. The viral plaques were counted microscopically 
and IC50 values were determined by linear regression analysis.  
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1.11. HCMV protease in vitro tests performed in Wade Gibson’s laboratory 
1. Preparation of enzyme.   
Assemblin containing a mutation at the I site and an N-terminal 6x His-tag was 
expressed in E. coli. A lysate was prepared in 8 M urea and assemblin was 
purified on a Ni-NTA column into 2 M urea. Assemblin was exchanged into 
refolding buffer (100 mM Na2PO4, pH8, 300 mM NaCl, 50 mM DTT, 15% 
glycerol). The concentration of enzyme was estimated on a SYPRO-Ruby stained 
SDS-PAGE by comparing with BSA standards run on the same gel. 
 
2. Preparation of substrate.   
SCMV pAP containing both a 6xHis-tag and a HWHWH-tag at its N-terminus 
was prepared and purified into 2 M urea as above. pAP concentration was 
estimated by measuring absorbance at 280 nm to be approximately 6 µM. 
 
3. Inhibition reactions.   
A 10-fold dilution series (3 mM to 3 µM) of each compound was prepared in 
DMSO. 10 µL of each inhibitor was added to 40 µL ddH20 and 50 µL 2x reaction 
buffer (100 mM Tris pH8, 1 M Na2SO4, 0.2 mM EDTA, 2 mM TCEP).  275 µL 
purified substrate was added to 275 µL 2x reaction buffer. 55 µL refolded 
assemblin (~3 µM) was added to 220 µL refolding buffer and 275 µL 2x reaction 
buffer. 10 µL substrate mix was added to 50 microfuge tubes, then 10 µL 
inhibitor was added to each tube, vortexed and briefly centrifuged. In  20 s 
intervals, 10 µL of enzyme mix was added, mixed by pipetting 3x and vortexing 
quickly on a low setting. After a 1 h incubation at room temperature 10 µL of 4x 
SDS-PAGE sample buffer was added in 20 s intervals and mixed thoroughly by 
pipetting and vortexing. Samples were stored at -80 C until analysis by SDS-
PAGE. 
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2. Results 
 
2.1. Optimization of the LexA-M yeast system for automated screening 
In order to identify small molecule inhibitors of HCMV protease, the yeast growth 
selection system based on reporter gene activation as described in Part I was applied to a 
high-throughput screening (HTS). A first batch of 3’040 compounds from the ChemDiv 
library was distributed in 38 96-well plates containing each 80 test compounds and was 
then screened against a VCY3 strain expressing the HCMV protease and its LexA-Me-
Gal4AD substrate. As specified in Part I, expression of HCMV protease was controlled 
by the ACT4 promoter and LexA-Me-Gal4AD by a truncated ADH1 promoter. 
Compounds were screened at a final concentration of ~50 µM for their ability to restore 
cell proliferation. A detailed description of the screening procedure is provided in 
Material and methods. 
Upon analysis of the preliminary results, we noticed that a problem occurred 
during this first screening phase: in each microtiter plate, OD600 in the wells of columns 1, 
4, 8 and 11 was systematically higher than in the other wells (Figure 1). OD600 in columns 
2, 5, and 9 was in the opposite lower, and this trend was independent of the nature of the 
compounds present in these particular columns. More precisely, the average of OD600 in 
column 8 (column exhibiting the highest OD600) after 30 hours incubation at 30°C was 
35% higher than the OD600 in column 2 (column exhibiting the lowest OD600). Given that 
hits are usually selected when they stimulate proliferation of the target expressing cells 
more than 5% or 10% relative to proliferation of the negative control (the same cells 
grown in the presence of DMSO), it is clear that the system as such was not usable for 
screening.   
To find solutions to this problem, we performed control tests where yeasts were 
grown in 96-well plates containing 1.5 µL DMSO per well instead of compound 
solutions. First, we removed glycerol from the assay medium, which reduced the “wavy 
pattern” to an OD600 difference of about 10% between column 2 and 8. In a second step 
3-AT was removed and the difference was further reduced to 5%. It seems that this 
“wavy pattern” was related to the robot mode of pipetting (robot fills 4 columns per 
aspiration step, what correlates with OD600 being always higher in the 4th column), 
however the cause of the phenomenon remains unexplained.  
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Thus, the LexA-M system as described in Part I was modified so that it could be 
used without glycerol and 3-AT. This reduced dramatically the difference of proliferation 
rates
 
between yeasts expressing the substrate alone and yeasts expressing the substrate 
and its protease. To extend the window between these two strain proliferation rates, we 
expressed the protease from the strongest promoter GAL1 instead of the ACT4 promoter, 
and the inoculation OD600, previously defined at 0.01, was decreased to 0.001. Despite 
these modifications, the 4-fold difference of proliferation rates measured in presence of 
glycerol and 3-AT, was reduced to 1.6 fold with the new assay conformation. The Z’ 
factor was lowered from 0.62 to 0.54. Table 1 summarizes the modifications that were 
applied to the screening system and the consequences of these modifications.  
  
2.2.  Screening and hit confirmation in yeast 
The 15’000 compound library was screened in this modified LexA-M system. An 
overview of the experimental procedure for the screening and for further characterization 
of the primary hits is outlined in Figure 2. A primary hit was defined as a compound that 
stimulates growth of HCMV protease expressing cultures more than 8% relative to 
growth of the negative control. Using this hit criterion, 259 compounds were found to be 
active in our assay. Among the 259 primary hits, 84 were confirmed to stimulate growth 
of HCMV protease expressing cultures more than 5% at any or all of these three 
concentrations: 50 µM, 25 µM and 12.5 µM.  
The fact that many screening hits are nonspecific represents a serious problem in 
early drug discovery. As mentioned in Part I, cell reporter system are prone to select for 
false positives interfering with LexA dimerization, LexA binding to DNA, with the 
transcription, translation or activity of His3p reporter protein, with the expression of 
LexA-M substrate or HCMV protease. It is expected however that bona fide inhibitors 
stimulate the proliferation of cells in a target-dependant manner. In order to eliminate 
unspecific compounds, the 84 hits were tested at 50 µM, 25 µM and 12.5 µM against the 
strain expressing the LexA-Me-Gal4AD substrate alone. 17 compounds stimulated 
growth in this strain at least at one concentration and were therefore discarded. The other 
67 compounds were considered as confirmed hits. 
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2.3.  In vitro FRET analysis of putative HCMV protease inhibitors 
In order to clarify whether the 67 hits identified in the screening directly inhibit the 
protease, they were tested in a fluorescence resonance energy transfer (FRET)-based in 
vitro assay, using the amino-4-methylcoumarin (AMC) substrate that is described in the 
Material and methods section. BI36 compound was used as positive control for this 
assay, and the calculated IC50 of 0.3 µM obtained in house was the same as the published 
IC50 (0.5 µM) (Yoakim, Ogilvie et al. 1998). 41 test compounds were inactive up to 100 
µM concentration and the remaining 26 compounds could not be evaluated due to 
precipitation, autofluorescence or quenching. Thus, none of the 67 test compounds was 
scored as positive in this biochemical assay. In order to circumvent the problems of 
fluorescence and quenching, another FRET substrate (Abz) was used, which absorbed 
and emitted at different wavelengths as AMC substrate. Yet, these problems were present 
at different degree at both wavelengths assessed.  
Even though the results of the biochemical assays did not show direct targeting of the 
protease, 44 compounds were reordered on the basis of their ability to promote 
proliferation of HCMV protease expressing yeast cells and of their protease specificity 
(they did not stimulate growth of the cells expressing the substrate alone, and they were 
also not selected in other in-house yeast screenings against other targets: BACE, P2A, c-
Met, EphB4).  
 
2.4. Antiviral assay for the evaluation of putative HCMV protease inhibitors 
In order to evaluate the potential of compounds to reduce cytomegalovirus proliferation 
in cell culture, we performed antiviral assays in mammalian cells. For this we used two 
different assays: an ELISA (Stahle, Schloss et al. 1998; Borthwick, Davies et al. 2003) to 
make a first selection of compounds potentially active against HCMV, and then a plaque 
reduction assay (PRA) (Landry, Stanat et al. 2000) to confirm compounds that were 
positive in the ELISA.  
Both GCV and BI36 positive controls were tested in ELISA, and the IC50 
calculated for these drugs was very close to the IC50 published in the literature. IC50 
values
 
between 0.29 µM and 11 µM were determined for GCV in PRA assays (Landry, 
Stanat et al. 2000), and our in house ELISA assay delivered for GCV an IC50 of 0.6 µM. 
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Similarly, we obtained a 60 µM IC50 for BI36, which is very close from the 78 µM IC50 
published by Yoakim et al. (Yoakim, Ogilvie et al. 1998). 
In contrast to the in vitro FRET assay, the evaluation of hits in the ELISA assay 
delivered several positives. Out of the 44 compounds tested, 11 showed activity against 
HCMV. Experiments with concentration ranges from 3 µM to 100 µM enabled to 
determine compound IC50 values with potencies varying from 8 µM for 150E10 to 65 µM 
for 71E2. A detail of each compound potency is given in Table II. In parallel to the 
ELISA assay, compound toxicity was assessed in an XTT cell viability assay (Roehm, 
Rodgers et al. 1991) (Table II). It has to be noticed that for many compounds, such as 
150E10, 107F6 and 107H6, a higher toxicity correlates with a better inhibitory potency. It 
is not possible however to determine if this effect is just a coincidence or if the intrinsic 
toxicity of the compounds has an effect on virus propagation. To calculate the viral 50% 
inhibition concentration (IC50), only compound concentrations that permitted at least 80% 
cell viability in comparison to the DMSO control were taken into account.  
In order to confirm these results, we tested the best candidates in a plaque 
reduction assay (PRA), which is the gold standard for antiviral susceptibility testing. Out 
of the 9 compounds tested in PRA assay, 8 obtained IC50 values in the same range as 
those calculated in ELISA (Table II).  
 
2.5. Evaluation of compound specificity towards HCMV by coxsackievirus (CV) 
inhibition tests 
8 compounds were confirmed as cytomegalovirus inhibitors in ELISA and PRA assays. 
In order to establish if these compounds were specific for HCMV or if they would also 
inhibit other viruses, we infected HEK293 cells with CV and measured via an ELISA 
assay if our compounds were effective in preventing CV proliferation. Like HCMV, CV 
relies on a protease for its replication, but the two proteases have different modes of 
action: the HCMV protease uses a serine to catalyze the hydrolysis reaction, whereas the 
CV protease works with a cysteine. Thus, we anticipated that our putative HCMV 
protease inhibitors would not inhibit CV. However, on the 12 compounds tested (Table 
III), only 4 were specific for HCMV and did not inhibit CV. These compounds included 
ganciclovir, 19A2, 38F7 and 107H6. The 8 other compounds lowered the titer of CV in 
culture, and among them BI31 control was very potent (with an IC50 of 13.2 µM) against 
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this virus. Compound 150E10 was again the most efficient inhibitor of the batch with an 
IC50 of 8.4 µM, i.e. the same IC50 as the one calculated for HCMV. And again, like in the 
HCMV ELISA assay, the compounds that exhibited the highest toxicity were also the 
most potent against CV. To investigate whether compound toxicity could per se inhibit 
virus propagation, we tested if unrelated compounds that had been selected in screens 
targeting EphB4 kinase and β-secretase and that were moderately toxic also had an effect 
on virus proliferation. The 3 compounds presented on Figure 3, which toxicity varied 
from 15% to 50% at 100 µM, were shown to reduce HCMV proliferation in ELISA 
assay. It was verified that these randomly chosen compounds had no effect on HCMV 
protease in FRET and yeast assays.  
To summarize these antiviral assays, 8 test compounds out of 44 were potent against 
HCMV in both ELISA and PRA assay. However, 5 of them also inhibited CV, and we 
demonstrated that unrelated toxic compounds could also lower virus titer in ELISA assay. 
It has to be underlined however that out of the 44 compounds tested in ELISA against 
HCMV, 9 were toxic and showed no efficiency against the virus. 
 
2.6. Back to yeasts:  how do hits perform in assays with glycerol? 
As described in paragraph III.2.1, the primary screening in yeast had to be performed 
without glycerol and 3-AT, despite that glycerol was a key element for the catalytic 
efficiency of HCMV protease. Screening without glycerol was necessary to prevent the 
high cell density variations that were produced by the robot in 96-well plates. It was then 
decided to keep the same conditions to confirm the positives after the primary screening. 
But at the current stage of the compound characterization, we were interested to know 
how these compounds would perform in the different yeast assays under optimal 
conditions: in the LexA-M system with 10% glycerol and 10 mM 3-AT as described in 
Part I, and in the Trp1-M system with 10% glycerol, as described in Part II.  
Therefore, 10 hits positive in ELISA were tested at 50 µM, 16.6 µM and 5.5 µM 
in these two systems. The results of these growth assays for the 36 hours time point and 
the 50 µM concentration are summarized in tables IV and V. The BI31 and BI36 controls 
were the strongest growth activators in both assays, and this despite their toxicity. 
Generally, Trp1-M system delivered more positives than LexA-M system, and the 
amplitude of the stimulation was bigger. Only 107E7 and 150E10 were scored as 
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positives in both LexA-M and Trp1-M systems. However, it has to be underlined that the 
data presented in the tables III and IV represent only one time point and one compound 
concentration. Several compounds were scored as positives at other time points or 
concentrations. As a matter of fact, most compounds activated cell proliferation in certain 
conditions, but not in others. Only BI compounds activated growth at every time points 
and concentrations.  
 
2.7.   Test of published HCMV protease inhibitors in the automated screening set-up 
At the time when the HTS was done no HCMV protease inhibitor was available. The 
BI31, BI35 and BI36 compounds (Yoakim, Ogilvie et al. 1998) were sent to us by 
Boehringer Ingelheim only several months later. Instead of a protease antagonist, 0.15% 
glucose was used as positive control, because glucose represses the expression of HCMV 
protease driven by the GAL1 promoter and so mimics the effect of a HCMV protease 
inhibitor. Control experiments were performed with the series of truncated GAL1 
promoters to ensure that partial reduction of HCMV protease activity was detectable. 
However, considering the suboptimal conditions that were used during this HTS (III.2.1) 
and the low rate of hit confirmation in yeast LexA-M and Trp1-M systems with glycerol 
(III.2.6), it was important to find out whether all three BI compounds would have been 
scored as positives under the automated screening conditions.  
Therefore, cells were transformed with the LexA-Me-Gal4AD substrate and the 
HCMV protease expressed from the GAL1 promoter and were inoculated with a start 
OD600 of 0.001 in selective medium containing 2% galactose and the 3 BI compounds at 
50 µM, 16.6 µM and 5.5 µM. Pipetting was done by hand. This experiment showed that 
only BI36 would have been scored as positive in the 50 µM primary screening. With 15% 
growth activation at 50 µM after 36 hours of incubation, this compound boosted cell 
density over the 8% stimulation threshold (Table VI). Inhibition of HCMV protease by 
BI31 and BI35 compounds at 50 µM did not stimulate growth sufficiently to compensate 
for their pronounced toxicity. BI35 stimulated cell proliferation above the 8% threshold 
at 16.6 µM and 5.5 µM at all three time points, but BI31 never passed this limit. In the 
introduction of this thesis I emphasize that the utilization of cellular assays for screening 
enables the selection of non-toxic compounds. The non-selection of BI31 and BI35 by the 
automated LexA-M system could then be expected considering their toxicity. However, 
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given that these compounds activate strongly in both LexA-M and Trp1-M systems in 
presence of glycerol, these negative results are not in favor of the LexA-M system as it 
was used for automated screening. Best example is given by BI36, which at 50 µM had 
passed the IC50 in the systems with glycerol (II.3.5). In the automated screening 
configuration, it stimulated cell proliferation only 15% at 50 µM, when a complete 
protease inactivation would produce 60% stimulation. Thus, this experiment shows that 
the LexA-M system as it was used in automated screening was not optimal and that an 
alternative would have to be searched to solve the “wavy pattern” that resulted from robot 
pipetting. 
 
2.8.  Western blot to show direct effect of compounds on protease activity 
8 compounds had shown antiviral properties in both ELISA and PRA assays, and some of 
them such as for example 150E10 or 107H6 even presented IC50 values in the low 
micromolar range. However, some concerns were raised regarding a potential effect of 
their toxicity on the virus proliferation, and we needed to demonstrate that these 
compounds directly targeted protease activity. So far, none of these 8 compounds was 
shown to be active in in vitro assays, and their efficiency in yeast and in mammalian cell 
assays could be attributed to a mechanism independent of HCMV protease inhibition. 
In order to find out whether the compounds directly inhibited the protease, 
Western blot analysis was performed as exemplified with BI36 in the Part II of this 
thesis. RLY07 strain expressing Trp1194-Me substrate and HCMV protease was incubated 
during 16 hours in growth medium containing the test compounds, BI36 (positive 
control) or DMSO (negative control). Extracts were loaded on an SDS-gel and analyzed 
by Western blot. Figure 4 shows that BI36 control as well as 19A3 (weakly), 71E2, 
112H10 and 150E10 seem to prevent cleavage of Trp1194-Me substrate. However, 
similarly to the results presented in paragraphs II.3.3 and II.3.5, no cleavage product 
could be detected after proteolysis. It was thereof impossible to know if test compounds 
really inhibited cleavage or if they caused the overexpression of the Trp1194-Me substrate. 
In the same manner, it was impossible to discriminate whether compound caused the 
underexpression of the protease or if they inhibited it. 
Therefore, many efforts were invested to detect those proteolysis fragments, 
which should migrate at 24 kDa (N-terminus) and 6 kDa proteins (C-terminus). 1) In 
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order to improve the signal given by the Trp1194-Me substrate and its cleavage products, 
different tags were tested. FLAG, Myc, and triple-HA were added to the N-terminus, but 
cleavage fragments remained undetected. 2) Presuming that the C-terminal 6 kDa 
fragment would be too small to be detected we fused a 26 kDa GST group at the end of 
the Trp1194-Me molecule. But neither the 24 kDa N-terminal fragment nor the new 30 
kDa C-terminal fragment could be detected. 3) To make sure that fragments were not 
below the detection threshold of the Western blot Trp1194-Me substrate was expressed 
from the ACT4 promoter, which is stronger than the truncated ADH1 promoter that was 
used so far. But still at this high expression level no 24 kDa band was detected. 4) 
MG132 proteasome inhibitor was added to the growth medium to prevent post-cleavage 
degradation of Trp1194-Me fragments. This alternative approach also did not allow 
detection of proteolysis fragments.  
Thus, despite many efforts, we were not able to detect a product resulting from 
the cleavage of Trp1194-Me substrate by the HCMV protease. As a consequence, we 
cannot unequivocally conclude that compounds inhibit protease activity.  
 
2.9.  Effect of hits on in vitro cleavage of pAP 
Cleavage inhibition of different FRET substrates has been investigated in biochemical 
assays (III.2.3). But several hits were either fluorescent or quenchers and could therefore 
not be tested. All commercially available substrates being small peptides (6-12 amino 
acids), their cleavage cannot be addressed by electrophoresis. I found no way to 
demonstrate in house a direct effect of our compounds on proteolysis by HCMV protease. 
Therefore, I requested the collaboration of Professor Wade Gibson (Johns Hopkins 
University School of Medicine, Baltimore), who has a long time experience with HCMV 
protease. He performed the following experiment: the natural HCMV protease substrate, 
pAP, was incubated during 1 hour with assemblin and compounds at 0.1 µM, 1 µM, 10 
µM and 100 µM. Then reactions were loaded on an electrophoresis gel, and proteins were 
colored with SYPRO-Ruby stain. Results are depicted on Figure 5. The 41 kDa full-
length pAP (lane 1) was cleaved at the M-site and fragments of 35 kDa and 6 kDa (the 
smaller is not visible on the gel) were released (lane 2). On the right, BI36 control clearly 
inhibits proteolysis of pAP at 100 µM and 10 µM. By contrast, none of the hits inhibits 
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HCMV protease in this assay. Thus, it seems that none of our hits is active in vitro on the 
HCMV protease. 
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3. Discussion 
 
In order to select for HCMV protease inhibitors, the LexA-M system that was developed 
in Part I of this thesis had to be modified to suit to automated screening conditions. A 
15’000 small molecule library was screened and 67 hits were selected for their ability to 
stimulate proliferation of the protease-expressing strain above an 8% threshold. These 
compounds activated growth in a protease-dependant and dose-dependant way. 
 These hits were further tested in mammalian cell assays (ELISA and PRA), and, 
among them, 8 compounds showed good antiviral properties. It was not clear though, if 
this effect was due to the inhibition of the viral protease or to general toxicity of the 
compounds. In attempts to show that these compounds were targeting the protease, we 
tested them first in in vitro FRET assays, where they were either inactive or could not be 
investigated because of their fluorescence or quenching properties. In an additional test, 
their influence on the cleavage of the TRP1194-M substrate in yeast was evaluated by 
Western blot. However, this experiment did not allow discriminating between bona fide 
inhibitors and compounds that would modify substrate or protease expression.  Finally, 
the ability of compounds to prevent the cleavage of the natural substrate pAP in vitro was 
examined. In this assay performed in the laboratory of Professor Gibson (Johns Hopkins 
University School of Medicine, Baltimore) none of the hits was able to prevent cleavage 
under these experimental conditions. Thus, no evidence of direct inhibition of HCMV 
protease by the identified hits could be produced by all these experiments taken together. 
 
3.1.  Reasons for the lack of direct protease inhibition of the selected hit 
compounds 
There are several explanations why no inhibitor has been identified, which would have 
been active not only in yeast and mammalian cell assays, but also in biochemical assays. 
First, as discussed in chapter III.2.1 and III.2.7, the conditions applied for HTS were not 
optimal. In the absence of glycerol, the sensitivity of the LexA-M system was reduced. 
This was illustrated by the BI36 control. This compound, a potent HCMV protease 
inhibitor, stimulated growth only 15% as compared to 94% in the same system with 
glycerol. If another HTS had to be performed, we would add 10% glycerol to the 
selection medium and solve the “wavy pattern” problem (as described in III.2.1) such that 
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each screening plate column would be filled separately. In such a setup, each 
aspiration/distribution step would lead to the filling of one column, as compared to the 
filling of 4 columns per aspiration step in the original screening.  
Another argument to explain the lack of convincing inhibitors is the limited size 
of the library. Indeed, our library consists of only 15’000 compounds, which is far away 
from the typical multimillion compound libraries of pharmaceutical companies (Coburn, 
Stachel et al. 2004).  
Finally, it has to be underlined that HCMV protease is a difficult target for all 
types of screening assays. This enzyme was first described in 1991 (Welch, Woods et al. 
1991), and crystallized in 1996 (Chen, Tsuge et al. 1996; Qiu, Culp et al. 1996; Shieh, 
Kurumbail et al. 1996; Tong, Qian et al. 1996). Intensive researches were carried out to 
identify new protease-targeting drugs that would replace or complement HCMV current 
therapies. However, no inhibitor entered clinical trials so far. The difficulty with HCMV 
protease resides in its poor activity (kcat 20min-1; (Pinko, Margosiak et al. 1995)) and in 
its status of obligate dimer (Kd 8µM; (Margosiak, Vanderpool et al. 1996)). Moreover, in 
opposition to other enzymes where the active site is nested in a deep cleft, the active site 
of HCMV protease is shallow (Chen, Tsuge et al. 1996). As a result, chemical 
compounds have few possibilities to bind. Therefore, most inhibitors published so far 
bind covalently to the enzyme, either by alkylation of the active Ser 132 (Deziel and 
Malenfant 1998; Borthwick, Exall et al. 2002), or by oxidation of cysteine residues 
(Baum, Ding et al. 1996). Since potential interactions between the enzyme and its 
inhibitors are reduced due to shallowness of the active site, it is also difficult to design 
inhibitors that are selective. The possibility of cross-reactivity with other enzymes, 
particularly proteases, becomes a concern. 
 
3.2. Dimerization inhibitors versus active site inhibitors 
So far, the strategies to target the herpesviral proteases were mostly based on active site 
inhibition. However, allosteric inhibition is gaining interest. It was shown for example 
that dimer disruption totally inhibits KSHV protease activity (Shimba, Nomura et al. 
2004). In the same way, single mutations at the dimer interface of HCMV protease, even 
if they do not impair dimerization, inhibit catalytic efficiency (Batra 2001). A 
mutagenesis study of KSHV protease (Pray, Reiling et al. 2002) showed that the dimer 
 60
interface is finely developed and sensitive to perturbations, which in turn greatly affect 
the activity of the enzyme. Thus, blocking the dimerization or altering the dimer interface 
would be as efficient as blocking the active site. Since the herpesviral protease interface 
consists of unique surface area, with deep grooves and large hydrophobic pockets (Chen, 
Tsuge et al. 1996), there are theoretically many binding possibilities for potent and 
specific inhibitory molecules.  
However, such dimerization inhibitors might not be selected by in vitro screening 
campaigns as they are usually performed. Indeed, to be able to screen with a reasonably 
low concentration of enzyme, researchers usually work with high concentrations of salt in 
the assay buffer, which artificially lower the Kd. Thus, it is possible to have an HCMV 
protease active at 50 nM, whereas natural Kd of the enzyme is 8 µM (Margosiak, 
Vanderpool et al. 1996). But we do not know if a dimerization inhibitor with a Ki of for 
example 300 nM would be able to compete with another monomer in such conditions. To 
evaluate to potency of a compound that disrupts dimerization, the assay should be 
performed in buffer containing physiological salt concentrations. 
These physiological conditions are precisely present in our yeast assays. 
Compounds are tested in a cytoplasmic environment, where no salt has been added. Thus, 
we might have selected dimerization inhibitors, and this could explain why none of our 
hits showed activity in vitro. There are other cases of compounds that are poorly active in 
biochemical assays but very potent in cell culture, such as, for example, Glivec, the first 
tyrosine-kinase inhibitor to be approved for the treatment of cancer. This small molecule 
binds to the inactive form of the oncogenic kinase BCR-ABL (Schindler, Bornmann et al. 
2000) and prevents its autophosphorysation. Since biochemical assays are usually 
performed with the active form of the enzyme, Glivec was not potent in vitro. 
In order to test whether selected hits disrupt dimerization of HCMV protease, a 
size exclusion chromatography could be performed. At 8 µM concentration the protease 
is in equilibrium between monomeric and dimeric enzyme configurations (Margosiak, 
Vanderpool et al. 1996). Chromatography should elucidate if the presence of a compound 
shifts this equilibrium towards monomeric state or not. However, this experiment would 
necessitate infrastructure and resources that we do not have. 
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3.3. Compounds active in antiviral assays: protease inhibitors or false positives? 
A big concern after this screening was the reliability of the inhibitors selected. No proof 
could be made that they directly targeted HCMV protease activity, neither in biochemical 
assays nor in Western blots. Moreover, even if they obviously inhibited virus 
proliferation in human cell assays, it was not clear if this effect was really due to protease 
inhibition or if it was an artifact caused by their toxicity. Indeed, since viruses use the cell 
machinery to replicate it is conceivable that altered cellular metabolism retard virus 
proliferation. An unsought experiment gave some credit to this hypothesis: during a 
weekend the temperature of the 37°C incubator dropped to 31°C when the virus culture 
was between the 4th and the 7th day of infection. As a consequence, no cytopathic effect 
(CPE) could be observed in these cultures after 7 days, whereas under normal conditions 
(37°C), large plaques are visible (data not shown). This shows that suboptimal cellular 
conditions impair virus proliferation. 
In paragraph III.2.5, the specificity of compounds towards HCMV was tested by 
examining their effect on coxsackievirus (CV). It was shown that several hits inhibited 
CV and were therefore not specific. However, it is important to mention that the essential 
protease of picornaviridae, the picornain cysteine 3C protease, shares similarities with 
HCMV protease. Crystal structures of different picornaviral 3C proteases resemble to 
those of the chymotrypsin family of serine proteases with the active site serine being 
replaced by a cysteine residue (Allaire, Chernaia et al. 1994; Malcolm 1995). The 
replacement of active site cysteine of poliovirus and CV 3C proteases with a serine 
results in catalytically active enzymes (Lawson and Semler 1990). Like herpesviruses 
proteases, 3C proteases are slow acting enzymes (Malcolm 1995), their active site is also 
located in a shallow cleft (Allaire, Chernaia et al. 1994), and the third member of their 
catalytic triad has only a minor role in catalytic mechanism (Allaire, Chernaia et al. 
1994). Importantly, these proteases are inhibited by related active site inhibitors, 
respectively β-lactams for herpesviruses proteases (Yoakim, Ogilvie et al. 1998; Gerona-
Navarro, Perez de Vega et al. 2004) and β-lactones for picornaviruses proteases (Lall, 
Ramtohul et al. 2002). It is thus conceivable that inhibitors could inhibit both proteases, 
as exemplified by the β-lactam BI31 in Part III.5. However, if our putative inhibitors 
would inhibit both protease active sites, they should be active in biochemical assays and 
they were not. And if they would prevent dimerization they should be specific for 
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HCMV, since picornaviruses proteases do not need to dimerize to be active (Peters, 
Kusov et al. 2005). 3 out of the 10 hits of table VII were selective towards HCMV; they 
were yet inactive in both yeast assays with glycerol. The other hits were not selective and 
inactive in biochemical assay.  
 
3.4. Chemical structure comparison between hits and validated HCMV protease 
inhibitors 
To investigate whether our putative inhibitors shared common chemical structures 
with known HCMV protease antagonists we compared the scaffold of published 
inhibitors with the structure of our hits. Interestingly, several hits are built on the same 
scaffold like known inhibitors. For example, compounds 107E7, 107F6 and 107H6 are 
isocoumarin derivatives. And 3,4-dichloroisocoumarin is a general serine inhibitor, which 
was shown to inhibit HCMV protease in vitro with an IC50 of 4 µM (Levine, Michener et 
al. 1997) (Figure 6A). Similarly, compound 54C8, a benzoxazinone derivative, was 
selected in the yeast screening but showed no activity in antiviral assays. This compound 
is built on the same scaffold like several herpesviral protease inhibitors that show IC50 
values in the low micromolar range (Jarvest, Parratt et al. 1996; Abood, Schretzman et al. 
1997) (Figure 6B). Unfortunately, no compound in the library was built on lactam 
scaffolds. We can then not determine if they would have been selected. However, we 
showed that the β-lactam BI36 would have been scored as positive in the yeast screening, 
and that it activated strongly in both LexA-M and Trp1-M assays with glycerol. 
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5.  Figures  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Illustration of OD600 variations between the columns of a microtiter plate when 
glycerol and 3-AT are used.  
 
 
 
 
Table I 
 
 
Hand optimized LexA-M assay Automated LexA-M assay 
Substrate promoter 
Protease promoter 
Medium 
 
Inoculation OD600 
ADHtr (TRP1 marker) 
ACT4 (URA3 marker) 
-HUT 2% glu + 10% glycerol 
+ 10 mM 3-AT 
0.01 
ADHtr (TRP1 marker) 
GAL1 (LEU2 marker) 
-HLT 2% gal 
 
0.001 
OD600 difference 
between the columns 
Maximal fold stimulation 
Z’ factor 
35% 
 
4x 
0.62 
5% 
 
1.6x 
0.54 
 
 
 
 
 
 
Figure 2 (next page). Overview of the experimental procedure for the screening and 
characterization of HCMV protease inhibitors. 
Test compounds 
 
B A 
OD600 
0.08 
0.13 
35% 
A: negative control    
(DMSO) 
 
B: positive control  
(0.15% glucose) 
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Figure 2 
 
16'000 compounds 
Primary screening 
Strain: VCY3 expressing LexA-Me-Gal4AD + HCMV protease 
Conc.: 50 µM 
Time points: 24h, 30h, 36h 
 
Growth stimulation  > 8% at one (or more) time point(s) 
 
259 compounds 
Confirmation of hits at 3 concentrations  
Strain: VCY3 expressing LexA-Me-Gal4AD + HCMV protease 
Conc.: 50 µM, 25 µM, 12.5 µM 
 
Growth stimulation > 5% at one (or more) concentration(s) and two (or more) 
time points, in two distinct runs 
 
84 compounds 
HCMV protease dependency test 
Strain: VCY3 expressing LexA-Me-Gal4AD  
Conc.: 50 µM, 25 µM, 12.5 µM 
 
Growth stimulation < 5% at three concentrations and three time points, in two 
distinct runs. 
 
67 compounds 
In vitro FRET assay 
Recombinant HCMV protease, AMC substrate 
Conc. up to 100 µM  
 
0 positive      Reordering on the basis of yeast results: 
26 compounds that precipitate,    percentage activation, dose-dependency,  
fluoresce or quench     selectivity against other targets 
 
 
44 compounds  
ELISA cellular assay 
Cells: MRC5; HCMV strain: AD169 
Concentrations: 100 µM, 50 µM, 25 µM, 12.5 µM, 6.25 µM, 3.125 µM 
 
 
 19A2, 19A3, 36C6, 38F7, 71E2, 71B3, 107H6, 107F6, 107E7, 112H10, 150E10 (Table I) 
 
 
Plaque reduction assay     ELISA with coxsackievirus (specificity) 
Cells: MRC5; HCMV strain: AD169    Cells: HEK293; coxsackievirus B3, strain Nancy 
Concentrations: 50 µM, 25 µM, 12.5 µM   Concentrations: 100 µM, 50 µM, 25 µM (or less) 
(or less)       
 
19A2, 19A3, 38F7, 71E2, 107E7,     19A2, 38F7, 107H6 (Table III) 
107F6, 112H10, 150E10 (Table II) 
 
Western blot 
Cells: RLY07 expressing TRP1194-Me + HCMV protease 
Concentration: 50 µM 
  
 19A3, 71E2, 112H10, 150E10 (Figure 4)
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Table II 
 
Anti-HCMV activity and cytotoxicity of selected compounds  
Compound IC50 in ELISAa IC50 in PRAa % toxicityb at 100 µM 
GCV 0.62 µM 3 µM  0% 
BI36  60 µM ND  6% 
19A2  53 µM 10 µM  25% 
19A3  34.5 µM > 12.5 µM* 18% 
36C6  51 µM > 250 µM 20% 
38F7  10 µM 30 µM  22% 
71E2 73.2 µM 83 µM  0% 
71B3  > 25 µM* ND  18% 
107E7 43 µM 50 µM  0% 
107F6  30 µM > 3 µM* 80% 
107H6  23 µM ND  60% 
112H10  60 µM  95 µM  0% 
150E10 8 µM 22 µM  80% 
a
 IC50: 50% inhibitory concentration 
b
 toxicity of compounds on MRC5 cells is measured by XTT assay 
* higher concentration tested; compounds precipitated or showed >20% 
toxicity above 
 
 
 
Table III 
 
Anti-CVB3 activity and cytotoxicity of selected compounds  
Compound IC50 in ELISA a % toxicityb at 100 µM 
GCV > 100 µM  0% 
BI31  13.2 µM 25% 
19A2  > 100 µM 10% 
19A3  55 µM 25% 
36C6  90 µM 10% 
38F7  > 100 µM  0% 
71E2 63.7 µM 10% 
71B3  > 25 µM* 20% 
107E7 > 25 µM* 50% 
107H6  > 100 µM 10% 
112H10  40 µM 25% 
150E10 8.4 µM 70% 
a
 IC50: 50% inhibitory concentration 
b
 toxicity of compounds on HEK293 cells is measured by XTT assay 
* higher concentration tested; compounds precipitated or showed > 20% 
toxicity above 
In bold: compounds that do not inhibit coxsackievirus 
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A. 
XTT assay
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Figure 3.  Unspecific, toxic compounds prevent HCMV proliferation in cell culture. A. 
Compound toxicity on MRC5 cells, as measured by XTT assay. The assay was made 7 
days after cell seeding and 5 days after the treatment with the compounds. B. Compound 
efficiency against HCMV, as measured by ELISA assay. Assay was performed 7 days 
after cell seeding and infection with HMCV, and 5 days after adding the compounds. 
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Table IV 
 
Hit validation in yeast: LexA-M system with 10% glycerol 
Compound 
Fold stimulation  
against active  
protease at 50 µM 
Fold stimulation  
against inactive  
protease at 50 µM 
BI31 1.27x 0.61x 
BI36  1.94x 0.86x 
19A2  0.95x 0.77x 
19A3  1.06x 1.1x 
36C6  1.18x 1.11x 
38F7  1.1x 1.08x 
71E2 0.86x 1x 
71B3  ND ND 
107E7 1.10x 0.96x 
107H6  1.06x 1.05x 
112H10  1.06x 1.02x 
150E10 1.12x 1.02x 
In bold: compounds that would have been scored as positives in the  
primary screen if this assay would have been used.  
 
 
Table V 
 
Hit validation in yeast: Trp1-M system with 10% glycerol 
Compound 
Fold stimulation  
against active  
protease at 50 µM 
Fold stimulation  
against inactive  
protease at 50 µM 
BI31 3,75x 0.61x 
BI36  6,1x 0.93x 
19A2  0.92x 0.80x 
19A3  5.44x 0.82x 
36C6  1.16x 0.98x 
38F7  0.54x 0.85x 
71E2 0.63x 0.96x 
71B3  0.4x 0.83x 
107E7 1.10x 0.73x 
107H6  1.06x 0.97x 
112H10  1.36x 0.97x 
150E10 3.78x 1.16x 
In bold: compounds that would have been scored as positives in the 
primary screen if this assay would have been used. 
 
 
Table VI 
 
Activity of BI compounds in LexA-M system in absence of glycerol at 36h 
Compound 
Fold stimulation  
against active  
protease at 50 µM 
Fold stimulation  
against inactive  
protease at 50 µM 
BI31 0.77x 0.60x 
BI35 1.05x 0.78x 
BI36  1.14x 0.87x 
In bold: compounds that would have been scored as positives in the  
primary screen   
Z’ factor: 0.62 
 
Maximal fold 
stimulation in case 
of total inhibition of 
active protease: 2.7x 
Z’ factor: 0.85 
 
Maximal fold 
stimulation in case of 
total inhibition of 
active protease:10x  
Z’ factor: 0.54 
 
Maximal fold 
stimulation in case 
of total inhibition of 
active protease:1.6x  
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Figure 4. Western blot analysis of yeast extracts to test whether hits prevent cleavage of 
the Trp1194-Me substrate by HCMV protease. RLY07 cells were transformed with 
Trp1194-Me alone (lane 1), Trp1194-Me and active protease (lane 2-12), or 2 empty 
plasmids (lane 13). Transformed cells were incubated in growth medium with the 
different hits at 50 µM (lane 3-11), with BI36 control at 50 µM (lane 12) or with DMSO 
(lane 1,2,13). The calmodulin antibody served as an internal control for protein amount. 
 
 
 
 
Figure 5. In vitro analysis of compound effect on pAP cleavage by HCMV protease. 1 
µM pAP substrate was incubated with 100 nM assemblin and different concentrations of 
compounds (0.1 µM, 1 µM, 10 µM, 100 µM) in assay buffer during 1 hour at RT. 
Cleavage was then addressed by SDS-PAGE. 
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B 
 
 
 
 
 
 
Figure 6: Comparison between hits (left) and published HCMV protease inhibitors 
(right).  
 
 
 
 
 
 
 
 
Table VII (next page): 
a: fold stimulation at 50 µM 
b: visual estimation of inhibition at 50 µM 
c: IC50: 50% inhibitory concentration 
d: % toxicity at 100 µM; toxicity is measured by XTT assays. 
* highest concentration tested; compounds precipitated or showed >10% toxicity above. 
In bold: characteristics expected from an HCMV protease inhibitor. 
O
O
OMe
107E7 
O
O
Cl
Cl
3,4-Dichloroisocoumarin 
54C8 Benzoxazinone 
N
N
O
O
O
O
O
O
CH3
CH3
Compound Structure
Western
blot b
FRET 
assay c
SDS-PAGE 
(Gibson) b
ELISA 
assay c 
(HCMV)
PRA
assay c 
(HCVM)
Toxicity 
on 
MRC5 
cells d
ELISA
assay c 
(CV)
Toxicity on 
HEK293 
cells d
HCMV
protease
No 
protease
HCMV
protease No protease
HCMV
protease No protease
BI31 0.77x 0.60x 1.27x 0.61x 3,75x 0.61x ND 1.8 µM ND 70 µM ND 15% 13.2 µM 25%
BI36 1.15x 0.87x 1.94x 0.86x 6,1x 0.93x
 +++ 0.3 µM  +++ 60 µM ND 6% ND ND
19A2 1.08x 0.84x 0.95x 0.77x 0.92x 0.80x
 - quenching  - 53 µM 10 µM 25% > 100 µM 10%
19A3 1.26x 1.23x 1.06x 1.10x 5.44x 0.82x
 + quenching  - 60 µM > 12.5 µM* 18% 55 µM 25%
36C6 1.08x 0.88x 1.18x 1.11x 1.16x 0.98x
 - quenching  - 51 µM > 250 µM 20% 90 µM 10%
38F7 1.19x 1.00x 1.10x 1.08x 0.54x 0.85x
 - quenching  - 10 µM 30 µM 10% > 100 µM 0%
71E2 1.20x 0.90x 0.86x 1.00x 0.63x 0.96x
 +++ quenching  - 65 µM 83 µM 0% 63.7 µM 10%
71B3 1.13x 0.92x ND ND 0.40x 0.83x ND quenching  - > 25 µM* ND 18% > 25 µM* 20%
107H6 1.09x 0.85x 1.06x 1.05x 1.06x 0.97x ND fluo  - 30 µM > 3 µM* 80% > 100 µM 10%
107E7 1.15x 0.99x 1.10x 0.96x 1.10x 0.73x
 - fluo  - 43 µM 50 µM 0% > 25 µM* 50%
112H10 1.15x 1.00x 1.06x 1.02x 1.36x 0.97x
 +++  -  - 60 µM 95 µM 0% 40 µM 25%
150E10 1.27x 0.95x 1.12x 1.02x 3.78x 1.16x
 +++ fluo  - 8 µM 22 µM 80% 8.4 µM 70%
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4. General conclusion 
 
Successful application of protease inhibitors in human therapy requires defined properties 
of drugs, such as membrane permeability, stability and lack of toxicity (Barberis 2002). 
While most HTS campaigns are performed with enzymatic in vitro assays, where 
compounds are selected exclusively in regard of their potential to inhibit proteolytic 
activity, cellular screening systems provide a promising alternative to select directly for 
compounds with additional drug-like features. Indeed, compounds identified as hits in 
living cells not only should inhibit proteolytic activity, but must also be stable within the 
cell, capable of penetrating biological membranes, and exert no or only limited toxic 
effects on the cell. 
 In this thesis, two yeast growth selection systems were developed to identify 
HCMV protease inhibitors: the LexA-M and the Trp1-M systems. The LexA-M system is 
based on other studies, which took advantage of the two functionally separable essential 
domains of Gal4p to measure proteolytic activity, either in mammalian cells (Lawler and 
Snyder 1999) or in yeast (Dasmahapatra, DiDomenico et al. 1992; Murray, Hung et al. 
1993). In these studies, the inactivation of the Gal4p transcription factor by a protease 
caused stop of transcription of a Gal4p regulated reporter gene. In our yeast system, 
HCMV protease similarly cleaves the M-site inserted between the two domains of Gal4p, 
and thus prevents transcription of the HIS3 reporter gene. As described in Part I, the 
optimization of the LexA-M system was a long process, and several key steps were 
necessary to improve HCMV protease efficiency in yeast, namely the replacement of the 
full-length protease precursor by the assemblin catalytic domain, the addition of glycerol 
in the selection medium and the elongation of the original 13 amino acid cleavage site to 
a 39 amino acid sequence. 
In Part II of this thesis, an alternative system was developed, which was based on 
a new concept but benefited from the experience accumulated during the development of 
the LexA-M system. In this Trp1-M system, the HCMV protease cleavage sequence is 
inserted into a yeast protein essential for cell proliferation, i.e. the yeast marker Trp1p. 
Cleavage and subsequent functional inactivation of Trp1p cause conditional growth 
arrest. Here like in the LexA-M system, protease activity correlates inversely with cell 
growth. Inhibition of the protease by small molecules stimulates the proliferation of the 
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cells. Thus, both systems are based on positive read-out and therefore select for non toxic 
compounds. HCMV protease inhibitors developed by Boehringer Ingelheim were used as 
positive control to validate these two systems (see II.3.5 and III.2.6).  
Both systems are equivalent in terms of sensitivity. I calculated for BI36 IC50 
values of 35 µM and 31 µM in the LexA-M and Trp1-M assays, respectively. However, 
the risk of selecting false positives is reduced in the Trp1-M system since the pathway 
leading to growth inhibition is shorter. Indeed, in this assay only compounds that interact 
with expression of the substrate or of the protease can show up as positives, whereas in 
the LexA-M system compounds might also interact with LexA dimerization, LexA 
binding to the DNA, HIS3 transcription, synthesis of His3p enzyme, activity of His3p 
enzyme. Thus, the Trp1-M system is probably more reliable. In any case, since the two 
assays are based on different mechanisms a compound scored as positive in both assays 
has a good chance to be a real positive. 
In this thesis, both systems are described as tools for the identification of HCMV 
protease inhibitors. But their use can be broadly extended. Screening for inhibitors should 
be possible for most viral proteases, like for example other herpesvirus proteases, 
picornavirus proteases, HIV protease, and also for human soluble proteases, like for 
instance caspases, cathepsins, calpains. For that matter, coxsackievirus 3C and varicella-
zoster virus proteases were expressed with their corresponding hybrid substrate in LexA-
“M” system, and they inhibited cell proliferation as expected (data not shown). The same 
was observed for coxsackievirus protease 3C in Trp1-“M” system (data not shown). 
Thus, our systems can be easily adapted for monitoring the activity of proteases other 
than HCMV protease. Moreover, they could theoretically also be used to identify 
substrates of orphan proteases, or conversely, proteases responsible for the cleavage of 
given substrates. Alternatively, a protease mutagenesis study could be made to increase 
the activity of a protease or to change its substrate specificity, like it was done by the 
DIREVO researchers, who engineered a standard protease so that it cleaves selectively 
TNFα  (http://www.direvo.de/press.html; press release of October 20th). 
In Part III, the LexA-M system was applied to a high-throughput screening for 
identification of HCMV protease inhibitors. The screening of 15’000 small molecules 
delivered 67 potential inhibitors, which counteracted the growth inhibition caused by 
HCMV protease. Among them, 8 compounds showed good antiviral properties against 
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HCMV in both ELISA and PRA mammalian cell assays. It was not clear though, if this 
effect was due to the inhibition of the viral protease or to the toxicity of the compounds. 
To address this question compounds were tested first in in vitro FRET assays, where they 
were either inactive or could not be investigated because of their fluorescence or 
quenching properties (Table VII). Next, their influence on the cleavage of the TRP1194-M 
substrate in yeast was evaluated by Western blot. However, this experiment did not allow 
discriminating between bona fide inhibitors and compounds that would modify substrate 
or protease expression.  Finally, the capacity of compounds to prevent the cleavage of the 
natural substrate pAP in vitro was examined. In this assay performed in the laboratory of 
Professor Gibson (Johns Hopkins University School of Medicine, Baltimore) none of the 
hits was able to prevent cleavage. However, as discussed in III.3, it is not excluded that 
our compounds inhibit dimerization of HCMV protease. In this case, hits might be 
inactive in biochemical assays because of the high salt concentration that is usually used 
in the buffers to force the dimerization and so keep the enzyme in an active conformation. 
Several reasons can explain why no inhibitor has been identified, which would 
have been active not only in yeast and mammalian cell assays, but also in biochemical 
assays. First, it has to be reminded that HCMV protease is a difficult target. Intensive 
researches have been carried out since more than 10 years to develop protease inhibitors, 
and so far to our knowledge none of them entered clinical trials (Waxman and Darke 
2000; Borthwick 2005). The difficulty with HCMV protease resides in the shallowness of 
its active site (Chen, Tsuge et al. 1996). As a result, chemical compounds have few 
possibilities to bind to the active site, and it is therefore difficult to design selective 
inhibitor. It is also the reason why most inhibitors published so far bind covalently to the 
enzyme (Deziel and Malenfant 1998; Borthwick, Exall et al. 2002; Baum, Ding et al. 
1996). As it is discussed in III.3, an elegant alternative to the active site inhibition would 
be the dimer disruption of the enzyme, which would also inhibit proteolytic activity. Such 
dimerization inhibitors would probably show a higher degree of specificity compared to 
active site inhibitors. 
A second argument to explain the lack of convincing inhibitors is the limited size 
of the library. Indeed, our library consists only of 15’000 compounds, which is far away 
from the typical multimillion compound libraries of pharmaceutical companies (Coburn, 
Stachel et al. 2004).  
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And finally, as discussed in chapter III.2.1 and III.2.7, the conditions applied for 
HTS screening were not optimal. To ensure a homogeneous cell culture pipetting by the 
robot in microtiter plates, glycerol was removed from the selecting medium, whereas it 
was shown that this chemical greatly improves protease efficiency (I.2.4). As a 
consequence the sensitivity of the LexA-M system was reduced. Therefore, if a new 
screening would be performed we would search another solution to solve the “wavy 
pattern” problem. 
In summary, even if encouraging results were obtained for several compounds in 
different assays (150E10 for example is very potent in yeast and antiviral assays, and 
seems to inhibit cleavage in the Western blot), no evidence of direct inhibition of HCMV 
protease could be produced. For each compound, the data collected present discrepancies 
(see Table VII): some compounds were active in one or two yeast assay(s), but not in the 
other(s); for many of them, no reduction of cleavage was observed in Western blot; in 
mammalian cell assays, most compounds were not specific and inhibited both HCMV 
and CV. Thus, considering in particular the lack of evidence of protease inhibition by our 
hits in biochemical assay, it has been decided to not develop these hits further. 
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5.  Appendix 
 
 
5.1.  Yeast plasmids and promoters 
 
 
CEN4-ARS1 versus 2 micron (2µ): 
CEN4-ARS1 plasmid: single copy plasmid ( => low intracellular protein concentration)  
2 micron (2µ) plasmid: high copy plasmid ( => high intracellular protein concentration)  
 
 
Level of protein expression with following promoters and plasmids: 
(LacZ reporter gene was cloned under the following promoters, and expression of β-
galactosidase was normalized to Gal1 promoter) 
 
Promoter    Plasmid (ori)    β-gal value 
ADHtr: truncated ADH1   CEN4-ARS1     0.8 % 
ADHfl: full-length ADH1  CEN4-ARS1     2.5 % 
ADHtr: truncated ADH1   2µ     5 % 
Gal1 truncated 7%   CEN4-ARS1     7 % 
ACT4     CEN4-ARS1     8.5 % 
Gal1 truncated 16%   CEN4-ARS1     16 % 
Gal1 truncated 46%   CEN4-ARS1     46 % 
Gal1 truncated 71%   CEN4-ARS1     71 % 
ADHfl: full-length ADH1  2µ     95 % 
Gal1fl     CEN4-ARS1     100 % 
ACT4     2µ     250 % 
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5.2. Abbreviations 
 
HCMV: Human cytomegalovirus 
CV:  Coxsackievirus 
VZV:  Varicella-zoster virus 
HSV1:  Herpes simplex virus I 
 
pAP:  Assembly protein precursor (natural substrate of HCMV protease) 
pPR:  Protease precursor (immature form of HCMV protease) 
 
PFU:  Plaque forming unit; number of infectious virus particles per unit volume. 
MOI:  Multiplicity of infection; number of infectious virus particles per cell in a 
specific experiment. 
CPE:   Cytopathic effect; symptom of viral infection in a cell culture. 
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